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Siddha system of medicine is the most pristine traditional medical system. The 
system was established about more than 5000 years back by the eminent powers 
called Siddhars and hence the name is Siddha medicine. Siddha system of medicine 
has grown with culture background and lifestyle of Dravidans. 
Siddham means “ARIVU” (or) “COMPLETE KNOWLEDGE”. 
The usage of traditional Siddha medicines for various ailments is increasing 
worldwide. As per the WHO more than 80 percentage of the world population 
currently use herbs and other form of traditional medicines to treat their diseases. 
In Siddha system, the paediatric medicine known as Kuzhanthai maruthuvam  
(or) Balavagadam, in whichdiseases are classified according to the age groups. 
In Balavagadam, diseases are mainly classified on two factors. 
1. Aga karana noigal 
2. Purakarana noigal 
According to Siddha system human body is comprised of 96 thathuvangal 
(principles), 72000 naadi narambugal (nerves and blood vessels), 7 udal thathukal, 3 
uyir thathukal. Imbalance in any of these constituents lead to Rogam (diseases) 
“Kabathinai andri kasa swasam kanathu” 
The above siddha verse quoted by Theran, means the Bronchial asthma (Sooli 
kanam) occurs due to alteration (or) defection inkaba kutram. 
Asthma is a Greek word which means „Shortness of breath, a panting‟ 
Asthma is a chronic reversible inflammatory disease of the airways 
characterised by recurrent paroxysmal attacks of dyspnoeachiefly expiratory in nature 
accompanied by wheeze which may subside spontaneously or with treatment.
[1]
 
In siddha system of medicine Bronchial Asthma is compared with Iraippu in 
the case of adults. In the case of children, it is compared with Sooli Kanam, which is 
one of the 24 types of Kanam, mentioned in Balavagadam. 
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The prevalence of Bronchial Asthma has increased continuously since the 
1970s, and now affects an estimated 4 to 7% of the people worldwide. In India the 
overall mean prevalence was found to be 2.74. The study done in urban and rural 
children in Tamil Nadu in the age group of (6 – 12) years showed prevalence of 
wheeze 18%. 
Rapid urbanization of our country and increasing number of vehicles leads to 
air pollution, which is one of the main factors responsible for Childhood Bronchial 
Asthma. Moreover, children are more susceptible to respiratory disorders due to 
various factors like poor immunity, low lung recoil, floppy chest wall weak 
respiratory muscles. If untreated affected children are continued to be lived with this 
disease for life long. As children are the futures of tomorrow, they must get rid of the 
major socio economic disease, Bronchial Asthma and as a doctor, we have 
responsibility for this. Though modern treatment like inhalers gives temporary relief, 
permanent cure can be achieved through traditional Siddha system of medicine 
without any side effects and cost effective manner. According to the verse “Ver Paru 
Thazhai Paaru Minjinakkal Mella Mella Parpa Chendhooram Paru” I chose 
Athimathura chooranam, a herbal formulation for the management of Kanam 













AIM & OBJECTIVES 
AIM: 
The aim of the study is select the cases of SOOLI KANAM (Childhood Bronchial 
asthma)   patients to administrate them with the trial drugs as per the line of treatment 
and analysis both clinically and experimentally to prove the safety and efficacy 
of“ATHIMADHURA CHOORANAM” for the treatment of SOOLI KANAM 
(Childhood Bronchial asthma) 
OBJECTIVES: 
 PRIMARY OBJECTIVE: 
To study the therapeutic efficacy of the medicine “ATHIMADHURA 
CHOORANAM” in the treatment of SOOLI KANAM (Childhood Bronchial 
asthma) 
SECONDARY OBJECTIVE: 
The main objective of the present study is to create the knowledge about the Siddha 
system and to highlight the efficacy of Siddha drugs among the people. 
To explore the etiology, clinical features, diagnosis and investigation of sooli kanam 
through various Siddha literature  
  To collect and review the ideas mentioned in the primordial Siddha literature about 
the disease Sooli kanam  
  To make the comparative study of the Siddha and Modern aspects of the disease  
                 To study the pre –clinical analytical standardization and safety study in the 
experimental formulation of the Athimadhura chooranam. 
 To evaluate the pharmacological study of the trial drug 
To educate the parents and children who were affected by the disease and how to 




 To conduct the clinical trial to find out the efficacy of Athimadhura 
chooranam,  To have a detailed analysis of the disease Sooli kanam(Childhood 
























REVIEW OF LITERATURE 
SIDDHA ASPECT 
இ஦ல்: (DEFINITION) 
க஠ம் ஋ன்தது கர்ப்தச்சூடு ஋ணக் கூறு஬ர்.஥ாந்஡த்஡ின் த஡ாடர் ந஢ாந஦ 
க஠஥ாகும்.இது கு஫஬ிக்கு, ஥ாந்஡ ந஢ாய் ஌ற்தட்டு ப௃ழு஬தும் 
கு஠஥ாகா஥ல் உடனில் இபேந்ந஡ ப௃ற்நி ஬பேம். கு஫ந்த஡கள் தாலும் 
குடித்து ந ாறும் உண்ணும் தபே஬த்஡ில் உண்டாகும் ந஢ா஦ாகும்.இது 
கு஫ந்த஡கபது ப௄ன்நா஥ாண்டு ப௃஡ல் ஌஫ா஥ாண்டு ஬த஧ துன்தத்த஡க் 
தகாடுக்கும் ந஢ா஦ாகும். 
ந஢ாய் ஬பேம் ஬஫ி (ETIOLOGY) 
கு஫ந்த஡ ஥பேத்து஬ம் (தான ஬ாகடம்) த௄ல் க஠ம் ந஡ான்று஬஡ற்காண 
஬஫ிகதப தின்஬பே஥ாறு கூறுகிநது. 
“஍஦து கூடிற் தநன்நால் அரித஬஦ர் து஦஧ந் ஡ன்ணால் 
த ய்஦ாற் புணனபேத்஡ிச் த நி ன ந஡ாடந் ஡ன்ணால் 
 தத஦஧ ஬ல்கு னாளும் த ிப௅ட ஢ிபேந்஡ ஡ாலும் 
துய்஦ந஡ார் கு஫஬ி கட்குக் கணங்களுந் ந஡ான்று ஥ன்நந”. 
- கு஫ந்த஡ ஥பேத்து஬ம் 
ததாபேள்: 
1. ஍஦஥ாணது ஡ன்ணப஬ில் இபேந்து கூடு஬஡ாலும் 
2. அரித஬஦ர்க்கு (அரித஬஦ர் ஋ன்தது ததண்கபின் தபே஬ங்கபில் 
என்நாகும்). 




4. த ிப௅டன் இபேக்கும் ஡ா஦ின் தாதன உண்த஡ாலும் 
கு஫ந்த஡களுக்கு க஠ந஢ாய் ந஡ான்றும். 
ii) திறுத௄ல்கபில் கூநப்தட்டுள்ப ந஢ாய்஬பேம் ஬஫ி: 
கும்தப௃ணி தான஬ாகடம் ஋ன்னும் ஌ட்டில் க஠த்஡ின் ந஢ாய் ஬பேம் ஬஫ி 
தற்நி தின்஬பே஥ாறு கூறுகிநது. 
““juzpjdpNyAW NraUlYjdpNy tU fizNuhf tuyhW Nfs; 
 fdpTngW nfw;gkpy; nuzkJ #bdhy; NghfkJ kpF #bdhy; 
tputpDlNd gy Njhrkjpdhypdp jhapDl ghy; Nttpdhy; 
 tps;S gy tprkjhy; jPapDl fhq;ifaha; ,sntapY 
 nfhs;syhYk;; 
cuAkhfhukJ FiwAkjpdhypdp cz;Z ghy; Ngjkjpdhy; 
 cwkhfNt fLk; #LlNd cz;zyhy; Gspj;j tif cz;zyhYk; 
GiuNkTk; mjpf ngUk; fhutif jpd;gjhy; mj;jpaJ #L kpQ;rp 
 GfOhpa khkprk; fUfpaJ nuzNk tw;wpaJNt naOk;Gk;” 
   - Fk;gKdp ghythflk; ghly;vz;-451 (g.vz;:113). 
 fh;g;தம் ஡ரித்஡ிபேக்கும்  ஥஦த்஡ில் புண் ஌ற்தடு஬஡ாலும், உ஠வு 
஥ிகு஡ி஦ாக உட்தகாள்஬஡ாலும், ஡ாய்க்கு ஌ற்தடும் ந஡ா ங்கபாலும், 
஡ாய்தால் இறுகி கடிணப்தட்டு தகாள்஬஡ாலும், ஡ாய்க்கு தன ஬ிடங்கள் 
஌ற்தடு஬஡ாலும், உடல் சூட்டிணாலும், த஬஦ினில் ஡ிரி஬஡ாலும், உ஠வு 
குதந஬ாக உட்தகாள்஬஡ாலும், உட்தகாள்ளும் தானில் ஌ற்தடும் 
நத஡த்஡ிணாலும், ஥ிக சூடாண உ஠த஬ உட்தகாள்஬஡ாலும் புபித்஡ 
உ஠வு ஬தககதப உண்஠னாலும், கா஧஬தக உ஠வுகதப ஥ிகு஡ி஦ாக 
7 
 
தகாள்஬஡ாலும், கர்ப்தத஦ின் சூடு ஥ிகு஡ி஦ாகி கர்ப்தத்஡ில் உள்ப 
஥க஬ின் உடல் த஥னிந்து க஠ம் ந஡ான்றும். 
஡ிபே஬ள்ளு஬ ஢ா஦ணார் இ஦ற்நி஦ ஢஬஧த்஡ின்  ிந்஡ா஥஠ி-800 ஋ன்னும் 
த௄னில் தின்஬பே஥ாறு கூநப்தடுகிநது. 
      “தா஧ாண தகற்தத஬ட்தட ஥ீபேம் தக்கு஬த்஡ில் 
      ந஬஧ான் ஬ிந்து த஬பி தட்டு ந஦ாபி ஬ிழுந்஡ த஡ன்நாற் 
      கா஧ாண திண்டங் கணனினடி தட்டுக் காந்஡ி஦ிணாற் 
 கூ஧ாய் கணசு஧ த஥ய்து த஥ன்நந஦ான் கூநிநணந஥”. 
                                   - ஢஬஧த்஡ின்  ிந்஡ா஥஠ி-800 
ததாபேள்: 
தகற்தத஬ட்தட ஥ீநி஦ிபேக்கும் ந஢஧த்஡ில் கபேவுற்நிபேக்கும் ஡ாப௅டன் 
஡ந்த஡ ந ர்஬஡ால் கபே஬ாணது (திண்ட஥ாணது) கணனில் அடிதட்டு க஠ம் 
஬பேகிநது. 
“஡ன்஬ந்஡ிரி த஬த்஡ி஦ம்” ஋ன்னும் த௄னில் தின்஬பே஥ாறு கூநப்தடுகிநது. 
 “ ரீி஦ த஡ான்த஥ த ய்஡ ஡஬ீிதண ஡ந்த஡஦ாகப் 
      தாரினிப் திநப்திற் த ய்஡ தா஬ந஥ ஡ா஦஡ாகப் 
     நதரி஦  ஦க் கு஥஧ன் ஬ிநந்஡ினா கிந஥த்஡ப்நத 
     காரி஦ த ஬ினித் ஡ா஦ாய் க஠ம் ததந ஬பபேம் ஢ாபில்” 






ப௃ற்திந஬ி஦ில் த ய்஡ ஡஬ீிதணகள் ஡ந்த஡஦ாகவும் இப்திந஬ி஦ில் த ய்஡ 
஡஬ீிதணகள் ஡ா஦ாகவும் தகாண்டு  கு஥ா஧ணாகி஦ க஠ம் ந஡ான்றுகிநது. 
“ ஧நதந்஡ி஧ த஬த்஡ி஦ ப௃தநகள்” கர்ப்தி஠ி தானந஧ாக  ிகிச்த  
தின்஬பே஥ாறு கூறுகிநது. 
  “ந஡ான்று஥ய்஦ த஡ார்த்஡ந் ந஡ா஦ப்ததக 
         பென்று ஡ாகம் த ி஥ிகுந் துற்நிடில் 
         ஌ன்ந துன்தத஥ல்னாம் ஬ந்து சூழ்஡னால் 
 ஆன்ந ந ய்க்குக் கணங்களு஥ாகுந஥”. 
              -  ஧நதந்஡ி஧ த஬த்஡ி஦ ப௃தநகள் கர்ப்தி஠ி தானந஧ாக   
 ிகிச்த  (த.஋ண்:57) 
ததாபேள்: 
     ஥ிகு஡ி஦ாகக் கதத்த஡ ஬ிபேத்஡ி த ய்஦க்கூடி஦ த஡ார்த்஡ங்கதப 
 ாப்திடு஬஡ிணாலும் த ிப௅ம் அ஡ிக஥ாக இபேக்தக஦ில் ஡ண்஠ரீ் 
அபேந்து஬஡ிணாலும் தற்தன க஠ந஧ாகங்கள் கு஫ந்த஡களுக்கு 
உண்டாகும். 
ந஢ாய் ந஡ான்றும் ஬஦து: 
க஠ம் ந஡ான்றும் ஬஦து தற்நி தல்ந஬று கபேத்துகள் உள்பண.க஠ம் 
கு஫ந்த஡கள் தாலும் குடித்து ந ாறும் உண்ணும் தபே஬த்஡ில் ஬பேம் 
ந஢ா஦ாகும். இது கு஫ந்த஡஦ின் ப௄ன்நா஥ாண்டு ப௃஡ல் ஌஫ா஥ாண்டு 
஬த஧ ஬பேம் ந஢ாய் ஋ன்தத஡,  
        “஋ன்ணந஬ க஠ா ப௄ன்று ஬பேடந் த஡ாட்நட 




-஋ன்னும் த ய்ப௅ள் ஬ரிகபால் அநி஦னாம். 
இத஡ ஡஬ி஧, 
த஧஧ா  ந க஧ம் ஋னும் த௄னில் தானந஧ாக ஢ி஡ாண தடனத்஡ில் க஠ம் 
கு஫ந்த஡கபின் 12 ஬஦து ஬த஧஦ிலும் காணும் ந஢ாய் ஋ண கூறுகிநது. 
அ஡ா஬து 
       “஋ன்ந ந஡ார் க்த஠ கடாப௃஥ிப்தடி த஦ழுந்து ததாங்கி 
       ஢ின்ந நதர் த஡ிதணட்டு ஡ாணிதநந்஡ிபே ஥ாண்டின் ந஥னாய்க் 
       கன்நி஦ தானர் த஥ய்஦ிற் தன்ணி஧ண்டாண்டு காறும் 
 ஢ின்நிடு த஥ன்று ப௃ண்஠ா஠ிகழ்த்஡ிணன் ப௃ணி஬ணன்நந”. 
- த஧஧ா  ந க஧ம் (தானந஧ாக ஢ி஡ாணம்). 
 தான஬ாகடம் த௄னில் கீழ்காணு஥ாறு கூநப்தடுகிநது. 
   “஥னப௃ஞ்  னப௃ ஥ிகத் ஡யீ்ந்து ஥ார்தின஡ிக சு஧ங்காப௅ம் 
    ஥னப௃ம் ஬஦ிறு ஥ிக த஬ரிப௅ம் ஬ப஥ாய் ஡தனப௅ ஥ிக ஥஦க்கும் 
     னப௃ம் ஬஧ள் ஡ ீ஡ான் குதநப௅ம்  ண்டாபம் நதாலுட் சு஧஥ாம் 
 ஡னந஥ தன்ணி஧ண்டாண்டு ஥ட்டும் ஡ண஡ாய் ஬பேங் கு஠஥ிதுந஬”. 
-தான஬ாகடம். 
஋ணந஬, க஠஥ாணது கு஫ந்த஡ திநந்஡து ப௃஡ல் 12 ஆண்டு ஬த஧ 
ந஡ான்றும் ந஢ாய் ஋ணவும் தகாள்பனாம். 
கர்ப்தச் சூடு: (3 ப௃஡ல் 7 ஬஦து ஬த஧) 
“த஡ாதக஦ான் க஠ங்கள் ஋ல்னாம் கர்ப்தாச்சூடு”. 




கர்ப்தச்சூடு ஋ன்த஡ில் சூடு ஋ன்தது அ஫ல் ஡ாதுத஬ 
குநிப்த஡ாகும்.அகத்஡ி஦ர் ஬ல்னா஡ி ஢ாடி த௄னில் கபேத஬ காப்த஡ில் 
அ஫ல் ஡ாது஬ின் ப௃க்கி஦த்து஬த்த஡ப்தற்நி கீழ்கண்ட஬ாறு 
கூநப்தடுகிநது. 
        “தாண்த஥ ஋ன்ந ஬ிந்஡ங்நக ஊறும் நதாது 
        தாப௅஥ப்தா வ்ன்ணிந஦ாடு ஬ாப௅ந் ஡ாநண” 
                            -அகத்஡ி஦ர் ஬ல்னா஡ி ஢ாடி த௄ல் 
஬ிந்து சுந஧ா஠ி஡த்ந஡ாடு ந ர்த்து கபேவுறுத்லுக்கு துத஠ புரி஬து ஬ாப௅ 
(஬ா஡ம்) ஆகும்.அவ்஬ாறு உற்தத்஡ி஦ாண கபேத஬ காத்து ஬ப஧ த ய்஬து 
அ஫ல் ஡ாது஬ாகும். 
“஬ன்ணிப௅ம் ஬ாப௅வு ஥ா஦ிபேந் சுக்கினாம்”. 
-஡ிபே஥ந்஡ி஧ம். 
ந஢ாய் ஌ற்தட கா஧஠ங்கள்: 
அ஫ல் ஡ாதுவும் ஬பி஡ாதுவும் சுக்கினத்துடன் ந ர்ந்ந஡இபேக்கும் ஋ண 
஡ிபே஥ந்஡ி஧ம் த௄னில் கூநப்தடுகிநது. 
இவ்஬ிபே த௄ல்கபின் கூற்றுதடி சுக்கினத்துடன் அ஫ல் ஡ாது உள்பது ஋ண 
அநிaனாம்.இவ்஬ாறு சுக்கினத்துடன் கூடி஦ அ஫ல் ஡ாது ஡ன்ணப஬ில் 
஥ிகு஡ிதடு஬஡ால் சுக்கினத்஡ில் ஬ிகற்தம் ஌ற்தட்டு கபே஬ின் அ஫ல் ஡ாது 
஥ாறுதடுகிநது.இ஡ணால் கபே஬ிற்கு சூடு அ஡ிக஥ாகிநது.இ஡தணந஦ 
“கர்ப்தச்சூடு” ஋ணக் தகாள்பனாம். 
஥ாந்஡த்஡ின் த஡ாடர் ந஢ாந஦ க஠஥ாகும்: 




஥ந்஡ம் ஋ன்தது உபே஬ ஢ிதன஦ில் உடல்஢ிதன஦ில் ஥ந்஡ம், அ஡ா஬து 
஡ா஦ின் உ஠T த஫க்கங்கபால் குற்நங்கள் நகடதடப௅ம் நதாது 
கு஫ந்த஡களுக்கு ந஡ான்றும் நகாபாறுகள் ஥ாந்஡ ந஢ாய் ஆகும். 
   ஥ாந்஡ம் த஡ாடந்து ஢ிதனப்தா஡ால், 
உ஠஬ின்  ா஧ம் உடற்கட்டுகளுக்கு ந ர்஬஡ில் ஡தடகள் ஌ற்தடுகிநது. 
 ா஧ம் த ந்஢ீ஧ாக் ஥ாறும் ஡ன்த஥ தா஡ிக்கப்தடுகிநது.  
  ஥ற்ந உடற்கட்டுகள் நதாட஠ிக்கப்தடி஬஡ில் தா஡ிப்பு 
உடற்கட்டுகபின் ஬ன்த஥ குதநகிநது. 
க஠த்஡ின் குநிகு஠ங்கள் ந஡ான்றுகிநது. 
஬஦஡ிதண ததாறுத்து: 
க஠ம் ந஡ான்றும் ஬஦துப்தற்நி தின்஬பேம் ஬ரிகளுக்கு அநி஦னாம், 
 “஋ன்ணந஬ க஠ப௄ன்று ஬பேடந் த஡ாட்நட 
஌஫ாண்டு ஥ட்டுக்கு ஥ிபேக்குங்கானம்” 
                                         -தான஬ாகடம் 
஋ன்ந தாடனிணால் ப௄ன்று ஆண்டு ப௃஡ல் ஌ழு ஆண்டு ஬த஧ ஬பேம் 
ந஢ாய் ஋ன்தத஡ அநி஦னாம் 
க஠த்஡ின் ஬தககள்: 
     தன த௄ல்கபில் தன஬தககபில் க஠ம் ஬தகப்தடுத்஡ப்தட்டு 
இபேக்கிநது 
1. தான஬ாகடம் த௄னில் 24 ஬தக஦ாட கூநப்தடுகிநது. 
      “க஠ங்கட்நதர் ஬ிரித்஡தந஦க் நகள்஢ண் நாகக் 
   கண஬ாத் க஠ம்தித்஡ கணங் குபிர்ந்஡ 
      ஥஠஥ான் ந த்஥க஠ம் திள்தப கட்கு 
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 ஥ாந்஡க஠ம் அ஡ிற்திரிவு ஍ந்஡ாம் இப்தால் 
 து஠஥ா஢ீர்க் க஠ம்தி஧பிக் க஠ப௃ ஢ல்ன 
 சூனிக஠ஞ் சு஫ிக஠ ஥கா க஠ந்஡ான் 
 கு஠஥ாண ஊதுக஠ம் ஬஧ட்க஠ந்஡ான்’  
 தகா஡ிப்புக஠ம் ஬கீ்கக஠ம் இன்ணங் நகநப 
 நகநப ஢ீ திநக்க஠ப௃ம் அந்஡ கன்஡ன் 
 க஠ப௃ம்஥ந் ஡ா஧க஠ம் ஋ரிக ஠ந்஡ான் 
 ப௃நப஢ீ ஧ா஥க஠ம் ஆ஥க஠ த஥த்஡ 
        ப௃க்குக஠ம் ப௄னக஠ம் நத஧ா ஥த்஡ின்   
 ஬ாநப ிங் கிந஦ாடி஧த்஡ க஠஥ாம் ஋ல்னாம் 
  ஬பேத்துத஧த்஡ ஡ிபேதஃது ஢ாங்கு ஥ாகக் 
  நகாநபது இத஬஡ாநண ஥பேத்து த௄னின் 
 குநிப்தநிந்஡ார்க் கல்னா஥ல் ஥ற்நநார்க் நகந஡” 
                                -தான஬ாகடம் 
 
1. ஬பி க஠ம்                     13. ஬கீ்கக் க஠ம் 
2. அ஫ல் க஠ம்                    14. திநக் க஠ம் 
3. ஍஦ க஠ம்                      15. அந்஡கக் க஠ம் 
4. ஥ாந்஡ க஠ம்                   16. ஥ந்஡ா஧ க஠ம் 
5. ஢ீர்க் க஠ம்   17. ஋ரி க஠ம் 
6. தி஧பிக் க஠ம்                  18. ஢ீ஧ா஥ க஠ம் 
7. சூனி க஠ம்   19. ஆ஥ க஠ம் 
8. சு஫ி க஠ம்    20. ப௃க்கு க஠ம் 
9. ஥கா க஠ம்    21. ப௄ன க஠ம் 
10. ஊது க஠ம்     22. நத஧ா஥ க஠ம் 
11. ஬஧ள் க஠ம்                  23. ஧த்஡ க஠ம் 
12. தகா஡ிப்பு க஠ம்   24.  ிங்கி ஥ாந்஡ க஠ம் 
13 
 
2. அந஦ாத்஡ி஡ா ர் தான஬ாகடம் த௄னில் 24 ஬தக஦ாக 
கூநப்தடுகிநது. 
அத஬கள்: 
1. ஬பி க஠ம்       13. ஬கீ்க க஠ம் 
2. அ஫ற் க஠ம்      14. திநக் க஠ம் 
3. ஍஦ க஠ம்     15. அந்஡க் க஠ம் 
4.  ஥ாந்஡ க஠ம்    16. ஥ந்஡ா஧ க஠ம் 
5. ஢ீர்க் க஠ம்    17. ஋ரி க஠ம் 
6. தி஧பி க஠ம்    18. ஢ீ஧ா஥ க஠ம் 
7. சூனி க஠ம்   19. ஆ஥ க஠ம் 
8. சு஫ி க஠ம்   20. ப௃க்கு க஠ம் 
9. ஥கா க஠ம்              21. ப௄ன க஠ம் 
10. ஊது க஠ம்   22. நத஧ா஥ க஠ம் 
11. ஬஧ள் க஠ம்  23. ஧த்஡ க஠ம் 
12. தகா஡ிப்பு க஠ம்   24.  ிங்கி ஥ாந்஡ க஠ம் 
3. ஆ஬ி஦பிக்கும் அப௃஡ ப௃தநச் சுபேக்கம்- ஋னும் த௄ல் 23 
஬தக஦ாக கூறுகிநது. 
அத஬கள்: 
1. ஬ா஡ க஠ம்         13. ஬கீ்க க஠ம் 
2. தித்஡ க஠ம்          14. திநக் க஠ம் 
3.  ிநனத்து஥ க஠ம்         15. ஆ஥க் க஠ம் 
4.  ஥ாந்஡ க஠ம்       16. ஬நட் ி க஠ம் 
5.  ஢ீர்க் க஠ம்           17. ப௃க்கு க஠ம் 
6. தி஧பி க஠ம்  18. நதார்க் க஠ம் 
7. சூதனக் க஠ம்   19. இ஧த்஡ க஠ம் 
8. சு஫ி க஠ம்                20. ஢ச்சு ஥ாந்஡ க஠ம் 
9. ஥கா க஠ம்    21. ஊது ஥ாந்஡ க஠ம் 
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10. ஊது க஠ம்     22. ஋ரி க஠ம் 
11. ஬நட் ி க஠ம்     23. ஥ந்஡ா஧ க஠ம் 
12. தகா஡ிப்பு க஠ம் 
   “஡ாணாண ந஡த஧ க஠ம் ப௃க்கு க஠ாந்஡ான் 
       ஡ணி஦ாண ப௄ன க஠ம் நதார் க஠ந்஡ான் 
ஊ஠ான் ஧த்஡ க஠ம் ஬ிடா ஥ாந்஡ க஠ப௃ம் 
       ஊது ஥ாந்஡க் க஠஥ாம் ஥ாந்஡ க஠ந்஡ானும் 
நகாணாண ஥ந்஡ா஧ க஠ப௃ந் ஡ானும் 
       கூ஧ாண ஋ரிக஠஥ா ஥ிபேதத்து ப௄ன்றும் 
தாணாண க஠ங்கள் தன்ணி஧ண்டு ஥ட்டும் 
 தானகர்க்கு ந஢பேத஥ன்று தகர்ந்஡஡ாந஥”. 
                  - ஆ஬ி஦பிக்கும் அப௃஡ ப௃தநச் சுபேக்கம் 
4. ஆத்஥ ஧ட் ா஥ிர்஡ம் ஋னும் த஬த்஡ி஦  ா஧  ங்கி஧ம் ஋ன்னும் 
த௄னில் தின்஬பே஥ாறு கூநப்தடுகிநது. 
              “தா஧ப்தா க஠஬குப்பு த஡ிதணட்டாகும் 
   தாடிணார் ஬ா஡க஠ம் தித்஡க஠ந஥ாடு 
               ந஢஧ப்தா ந த்஥க஠ம் ஥ாந்஡க஠஥ின்ணம் 
                     ஢ீர்க்க஠ஞ் சூதனக்க஠ம் தி஧பிக஠ந்஡ான் 
   ா஧ப்தா ஊதுக஠ம் சு஫ிக஠ந்஡ான் 
                      ார்஬ாண ஥ாக஠ப௃ம் ஬஧ட்க஠ந்஡ான் 
  கூ஧ப்தா தகா஡ிப்புக஠ம் திநக்க஠ந்஡ான் 
                      குநிப்தநி஬ாத஦த஦ந்து க஠ப௃஥ாந஥” 
- ஆத்஥஧ட் ா஥ிர்஡ம். 
஥ாந்஡ ப௃஡ிர்ந்து, 
1. ஬ா஡ க஠ம்                 14. ஬கீ்க க஠ம் 
2. தித்஡ க஠ம்               15. ஆ஥க் க஠ம் 
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3. ந த்஥ க஠ம்            16. ந஡த஧க் க஠ம் 
4. ஥ாந்஡ க஠ம்     17. ப௃க்கு க஠ம் 
5. ஢ீர்க் க஠ம்    18. ப௄னக் க஠ம் 
6. சூதனக் க஠ம்    19. நதார்க் க஠ம் 
7. தி஧பிக் க஠ம்    20. இ஧த்஡க் க஠ம் 
8. ஊது க஠ம்    21. ஬ி஥ாந்஡ க஠ம் 
9. சு஫ி க஠ம்    22. ஊது ஥ாந்஡ க஠ம் 
10. ஥ா க஠ம்      23. அந்஡க் க஠ம் 
11. ஬஧ட் க஠ம்        24. ஥ந்஡ா஧ க஠ம் 
12. தகா஡ிப்பு க஠ம்            25. ஋ரி க஠ம் 
13. திநக் க஠ம் 
஋ண க஠ங்கள் 25 ஬தகப்தடும் 
5.த஧஧ா  ந க஧ம் ஋னும் த௄னில் க஠த்஡ின் ஬தககள்-18 ஋ன்று 
கூறுகிநது 
அ஡ா஬து, 
   “உ஧த஥னுங் கத஠கண் ப௃ன்நணபேத஧த்஡ா஬றுத஧ப்தடக் 
நகண்஥ின் 
    சு஧த஥னுற் கத஠ப௅த஥ான்று துங்கு஥க் கத஠ப௅த஥ான்று 
  ஢ி஧஬ி஦ ப௄ன ஥ி஧த்஡ ஢ீங்கபேம் ஬஧ட் ி த஬ப்புக் 
    கபேவுறு ஥ணனன் ஬ஙீ்கி கூடி஦ந஡ார் ஥ஞ்  ஠னீன் 
     ஢ீன஥ாங் க஠ாய்஦ிநணடு ஢ின்நிடு த஬ளுப்பு ஥ாகும் 
     ானந஬  த்஡ி ந஥லுந் ஡ப்தினா ஥ாந்஡ ந஥கம் 
     ந஥ன஡ாம் ஬ிதணகள் நதான ஥ிபேந்஡ிடுற் க஫ிச் ல் கா ம் 
    ஆன஥ாரிபே஥ த஬ய்ப்பு ஥ா஬ித஬ த஡ிதணட்டாந஥” 




1. ஬ா஡ கத஠    10. ஬ஙீ்கு கத஠ 
2. தித்஡ கத஠     11. த஬ளுப்பு கத஠ 
3. சு஧க் கத஠             12.  த்஡ி கத஠ 
4. அத்஡ிசு஧ கத஠   13. இ஧த்஡ கத஠ 
5. ஬஧ட் கத஠             14.ப௄னக் கத஠ 
6. ஬ான ந்஡ி஧ கத஠  15. கபேங் கத஠ 
7. ஥நகந்஡ி஧ கத஠    16. ஥ஞ் ட் கத஠ 
8. தூக்கு கத஠       17. ஢ினக் கத஠ 
9. அணற் கத஠          18. த஬ப்பு கத஠ 
6.Fk;gKdp ghythflk; vDk; E}y; fzj;ij 18 tifahf $WfpwJ. 
“khJ fdpNthbdp NfSk; nuhd;gjpy; NgU tifahdjp eP 
 kUT RuNkhbdp J}q;Ffiz nuj;jKk; twl;irNahL ntg;G fizAk; 
NghjNkhL tPq;fYk; mdy;fiz khe;jKk; kQ;rSk; ePykJTk; 
 nghq;fpLk; rh;j;jpNahL uj;jKk; NkfKlNd thNye;jpud;; thiy re;jpud; 
NkhJkpdp mj;jpapd; Ruf;fid kNfe;jpu cs;Snuhfk; ngahpitfs;  
         <nuhd;gjhk; 
 KiwahfNt apit tifa njhd;W Nkyjha; <uhW taJ kl;Lk; 
NfhjfY ghyiu thijaJ nra;Ank FzNkhlT rjq;fs;  
 $whfNtapdp NkyhYiuf;fpNwd; xt;nthd;Wk; Cd;wp mwpNa” 
 
   - Fk;gKdp ghythflk;. ghly;vz;:452 (g.vz;:114). 
அத஬கள்: 
1. சு஧க்கத஠                                 10. ஢ீனக் கத஠ 
2. தூங்கு கத஠                             11.  த்஡ிக் கத஠ 
3. ப௄னத஧த்஡க் கத஠                       12. த஧த்஡க் கத஠ 
4. ஬நட்த க் கத஠                         13. ந஥கக் கத஠ 
5. த஬ப்பு கத஠                              14. அத்஡ிச்சு஧ கத஠ 
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6. அணல் கத஠                              15. ஬நனந்஡ி஧க் கத஠ 
7. ஬ஙீ்கு கத஠                               16. ஬ான  ந்஡ி஧க் கத஠ 
8. ஥ாந்஡க் கத஠           17. ஥நகந்஡ி஧க் கத஠ 
9. ஥ஞ் ள் கத஠                              18.உள்ளு ந஧ாகக் கத஠ 
7. ஜ஬ீ஧ட் ா஥ிர்஡ம் ஋னும் த௄ல்-8 ஬தக஦ாக் கூறுகிநது. 
1.சூனி க஠ம்      5. ஥கா க஠ம் 
2. ப௃க்கு க஠ம்                              6. சு஫ி க஠ம் 
3. ஆ஥ க஠ம்                                7. க஫ி க஠ம் 
4. ந஡த஧ க஠ம்                             8. ஬஧ள் க஠ம் 
8. திள்தபப்தி஠ி ஬ாகடம் ஋னும் த௄ல் 8 ஬தக஦ாக கூறுகிநது. 
  1. ஬஧ள் க஠ம்                           5. ஥கா க஠ம் 
  2. ப௄ன க஠ம்                           6. ஥னக் க஠ம் 
  3.  ஡ீ க஠ம்                             7. குண்டனி஦ க஠ம் 
  4. இ஡஦ க஠ம்                           8. ஢ீர் க஠ம் 
9.஡ன்஬ந்஡ிரி த஬த்஡ி஦ம்  ஦ந஧ாக ஢ி஡ாணம் ஋ன்னும் த௄னின் தடி 8 
஬தக஦ாக கூறுப்தடுகிநது 
அத஬கள்: 
1 ஬ான  ஦ம் 
2. ஬஧ீ  ஦ம் 
3. ஡பே஠  ஦ம் 




10.  ஧நதந்஡ி஧ த஬த்஡ி஦ ப௃தநகள் கர்ப்தி஠ி தானந஧ாக ிகிச்த  
஋ன்னும் த௄ல் கூறும் ஬தககள் 
1. ஢ீர்க் க஠ம் 
2. ஬஧ட் க஠ம் 
3. ஋ரி க஠ம் 
4. சு஫ி க஠ம் 
5. ப௄ன க஠ம் 
6. ப௃க்கு க஠ம் 
7. ஬ிக் க஠ம் 
8. ஆ஥ க஠ம் 
஋ண க஠த்஡ின் ஬தககள் கூநப்தட்டுள்பண 
ப௃க்குற்ந ந஬றுதாடு: 
    உ஠஬ா஡ி த ஦ல், அக, புந கா஧஠ங்கபால் ஌ற்தடும் சுக்கின 
சுந஧ா஠ி஡ந஡ாடங்கபின் ந஬றுதாடுகபாலும் ஬ிந்துவுடன் உட்த ல்லும் 
தி஧ா஠ன், த஬பி஦ினிபேந்து காக்கும் அதாணன், கபேத஬ ஬பர்க்கும் 
உ஡ாணன் ஆகி஦ ஬ாப௅க்கள் தா஡ிப்ததடந்து அ஫ல் குற்நம் ஥ிகு஡ிதட்டு 
கர்ப்தச்சூடு உண்டாகிநது. ஥ிகு஡ிதட்ட அ஫னாணது கதத்஡ின் 
இபேப்திட஥ாண ஥ார்பு தகு஡ித஦ தற்நி தகாண்டு கதத்த஡ ஬பர்ச் ிததந 
த ய்து க஠த்஡ின் குநிகு஠ங்கதப உண்டாக்குகிநது 
சூனி க஠ம்: 
       கு஫ந்த஡களுக்கு உண்டாகும் கi஠஦ின் எபே ஬தக சூனி க஠ம் 
ஆகும் 
சூனிக்க஠ம்-஬ிபக்கம்: (தான஬ாகடம்) 
கh;ப்தத்஡ிநனற்தட்ட க஠ச்சூட்டிணால் கு஫ந்த஡களுக்குண்டாம் ஏர் 




   “உண்டாஞ் சூனிக் க஠ங்நகபாய் 
    உற்ந சு஬ா  ந஥நனலு ம்திதித் 
    ஡ண்டா இபே஥ல் ஥ிக உண்டாம் 
    த஡ாண்தட ஢ாவு ந஥஬ந்து 
    ந ாபேம் ததாபே஥ி ஬஦ிற்றுப்பும் 
    ஬ண்டார் ப௃தனப௅ங் குடி஦ாது 
    ஬தட஦ாய் ப௃கப௃ம் ஢ாறு஥ன்நந” 
 -தான஬ாகடம், த.஋ண்.294 
ததாபேள்: 
         ந஥ல்ப௃ச்சு உண்டா஡ல் 
         இபே஥ல் அ஡ிக஥ாக ஌ற்தடு஡ல் 
         த஢ஞ்சு, ஬ாய், த஡ாண்தட ஢ாக்கு த஬ந்து புண்஠ா஡ல் 
         ஬஦ிற்றுப் ததாபே஥ல் உண்டா஡ல் 
         ஡ாய்ப்தால் உண்஠  ி஧஥ம் 
ப௃கத்஡ில் ஢ாற்ந஥டிக்கும் ஋ன்று தன஬ாகடம் த௄னில் கூற்ப்தட்டுள்பது. 
த஢ஞ்சு஬ாய் த஡ாண்தட ஢ாவு 
ந஢பேறு த஬ந்து புண்஠ாய் 
துஞ் ல்஡ன் ப௃தனப௅ண்஠ாது 
சு஬ா ந஥ா டிபே஥ லுண்டாம் 
஡ஞ் ஥ாய் ஬஦ிறு ததாபே஥ித் 
஡ாய்ப௃தன ப௅ண்நடாட் டாது 
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கஞ் தன ப௃கப௃ம் ஢ாறும் 
க஠சூனிக் க஠஥ி ஡ாந஥”. 
“உடனது த஬ளுத்து ஢ாவும் 
உ஡டுக தப஦ிறும் த஬ந்து 
஡ிடப௃டன் ப௃தனப௅ண்஠ாது 
 ி஬ந்து஢ீ த஧ரிந்து ஬ழீும் 
அடர்஥ னம்தி ின் நதானா 
஡ல்னது த௃த஧த்து ஬ழீ்஡ல் 
தடர்சு஧ம் ஬஦ிற்று லுண்டாம் 
தகர்தகர்ப்த க஠஥ ஡ாநண”. 
                  திள்தபதி஠ி ஥பேத்து஬ம், தாகம்-2, த.஋ண்-334 
ததாபேள்: 
1. த஢ஞ்சு, த஡ாண்தட, ஢ா புண்஠ா஡ல் 
2. ஡ாய்ப்தால் உண்஠ாத஥ 
3. சு஬ா ம், இபே஥ல் 
4. ஬஦ிறு ததாபே஥ல் 
5. ப௃கம் ஢ாறு஡ல் 
6. உடல் த஬ளுத்஡ல் 
7. உ஡டு ஬஦ிறு புண்஠ா஡ல் 
8. ஢ீர் ஋ரிச் ல் 
9. ஥னச் ிக்கல் 





     ந஥ல்ப௄ச்சு, இபே஥ல் த஢ஞ்சு ஢ாவும் ஢ாதிப௅ம் புண்நதானிபேத்஡ல், 
தாலுண்஠ாத஥, ப௃க஢ாற்நம் ஋ன்னும் இக்கு஠ங்கதப உண்டாக்கும் 
஋ன்று ஜ஬ீ஧ட் ா஥ிர்஡ம்  ிநப்தா஦ி஧ம் த௄னில் சூனிக஠ந஧ாகம் ஋ன்ந 
஡தனப்தில் கூநப்தட்டுள்பது. 
                                  - ஜ஬ீ஧ட் ா஥ிர்஡ம் த.஋.ண்:288 
ந஢ாய் க஠ிப்பு (DIAGNOSIS):  
 ித்஡ ஥பேத்து஬ம் ந஢ாய்க஠ிப்பு: 
 தி஠ி஦நி ப௃தநத஥ 
 உ஦ிர் ஡ாதுக்கள் (ப௃க்குற்நம்) 
 உடல் ஡ாதுக்கள் (஌ழு உடற்கட்டுகள்) 
 தபே஬கானங்கள் 
 ஍஬தக ஢ினங்கள் 




 ந஥ற்கூநி஦ கா஧஠ிகபின் ஥ாறுதாடுகதப என்றுடன் என்று 
எப்திட்டு ந஢ாய் க஠ிக்கப்தடுகிநது. 
தி஠ி஦நிப௃தநத஥ 
1. ததாநி஦ால் அநி஡ல் 





சூனிக஠த்஡ில் ந஢ா஦ாபிக்கு காணும் குநிகு஠ங்கள்: 
1. ததாநி஦ால் அநி஡ல்: 
   ப௄க்கு – ப௄க்கு ஢ீர்தாய்஡ல் 
   ஢ா – நகாத஫ த௃த஧஡ல் 
   கண் –  ினந஬தன கண் ி஬த்஡ல் 
   காது – இ஦ல்பு 
   ந஡ால் –  ினந஬தன அரிப்பு ஡டிப்பு கா஠ால் 
2. புனணால்  அநி஡ல்  
   ஊறு – த஬ப்தம் 
   ஏத  – இ஦ல்பு 
   எபி – இ஦ல்பு 
   சுத஬ – இணிப்பு சுத஬ த஡ரி஡ல் 
   ஢ாற்நம் – ப௄க்கில்  பி  வ்வு ஡டிப்புறு஡ல் 
3. ஬ிணா஡ல் : (நகட்டநி஡ல்) 
  ஥பேத்து஬ன் ஡ன்தண ந஢ாக்கி ஬ந்஡ தி஠ிப௅ற்ந஬தணப் தற்நி 
அநி஦ ந஬ண்டி஦஬ற்தந அநிந்தும், ஡ன் ததாநி புனன்கபால் 
ந஢ா஦ாபி஦ின் ததாநி புனன் ஬஫ி஦ாய் உ஠ர்஬த஡ 
ந஢ா஦ாபி஦ிணிடத்ந஡ (அ) அ஬ன் ததற்நநார் சுற்நத்஡ாத஧க் 
தகாண்நடா அ஬ணது தத஦ர், ஬஦து, ஡ித஠, குடும்த ஬஧னாறு, 
உ஠வு த஫க்க஬஫க்கம், ப௃ந்த஡஦ ந஢ா஦ின் ஬஧னாறு, எவ்஬ாத஥ 
஬஧னாறு நதான்ந஬ற்தந அநி஡ல் ஆகும். 
உ஦ிர்஡ாதுக்கள்: 
  1 ஬ா஡ம்:  
சூனிக்க஠த்஡ில் கா஠ப்தடும் ஬ா஡த்஡ின் ஢ிதன: 
1. தி஧ா஠ன் - தா஡ிப்பு (ப௄ச் ி஬ிடல், ஬ாங்கனில்  ி஧஥ம்) 
2. அதாணன் - தா஡ிப்பு (஥னச் ிக்கல் உடல் ஬ன்த஥ குதந஡ல்) 
3. ஬ி஦ாணன் - தா஡ிப்பு (உடல் குன்று஡ல்) 
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4.  ஥ாணன் - தா஡ிப்பு (திந ஬ாப௅க்கதப கட்டுப்தடித்து஬஡ில் 
 ி஧஥ம்) 
5. உ஡ாணன் - தா஡ிப்பு (இபே஥ல் ஬ாந்஡ி, ந஥ல்ப௄ச்சு, நதச்த ானி 
குதந஡ல் உடல் ந ார்வு) 
6. ஢ாகன் - தா஡ிப்பு (தடித்஡ல் ஬ிதப஦ாடல் நதான்ந 
த ஦ல்கதப த ய்஦  ி஧஥ம்) 
7. கூர்஥ன் - இ஦ல்பு 
8. கிபேக஧ன் - தா஡ிப்பு (஬ா஦ில் நகாத஫ த௃த஧஡ல், இபே஥ல், 
ப௄க்கு ஢ீர் தாய்஡ல், த ி஦ின்த஥) 
9. ந஡஬஡த்஡ன் - தா஡ிப்பு ( ின ந஬தப ஥ிகுந்஡ அ ஡ி கா஠ல்) 
10. ஡ணஞ்த ஦ன். 
2.தித்஡ம்: 
சூனிக்க஠த்஡ில் தித்஡த்஡ின் ஢ிதன: 
1. அணற்தித்஡ - தா஡ிப்பு (த ி஦ின்த஥, த ரி஦ாத஥) 
2. இ஧ஞ் கதித்஡ம் - தா஡ிப்பு (உடல் த஬ளுப்பு) 
3.  ா஡கப்தித்஡ம் - தா஡ிப்பு (அன்நாட ந஬தனகதப 
த ய்஬஡ில்  ி஧஥ம்). 
4. தி஧ா கம் -  ின ந஬தன தா஡ிப்பு (ந஡ானில் அரிப்பு) 
5. ஆநனா கம் - இ஦ல்பு 
3.கதம்: 
சூனிக஠த்஡ின் கதத்஡ின் ஢ிதன: 
1. அ஬னம்தகம் – தா஡ிப்பு (ப௄ச்சு ஬ிட  ி஧஥ம்) 
2. கிநன஡கம் – தா஡ிப்பு (த ரி஦ாத஥) 
3. நதா஡கம் – இ஦ல்பு 
4. ஡ற்தகம் –  ினந஬தப தா஡ிப்பு (கண்  ி஬த்஡ல்) 




சூனிக஠த்஡ில் உடற்கட்டுகபின் ஢ிதன 
1.  ா஧ம் – தா஡ிப்பு (உடல் ந ார்வு, உடல்குன்நல்) 
2. த ந்஢ீர் – தா஡ிப்பு (உடல் த஬ளுப்பு) 
3. ஊண் – தா஡ிப்பு (உடல் இதபப்பு) 
4. தகாழுப்பு – இ஦ல்பு 
5. ஋ன்பு – இ஦ல்பு 
6. ப௄தப – இ஦ல்பு 
7.  த஬ண்஠ரீ்/சுந஧ா஠ி஡ம் 
தபே஬கானங்கள் 
1. கார்கானம் – ஆ஬஠ி, பு஧ட்டா ி (Aug, Sep) 
2. கூ஡ிர்கானம் – ஍ப்த ி, கார்த்஡ிதக (Oct, Nov) 
3. ப௃ன்தணி – ஥ார்க஫ி, த஡ (Dec, Jan) 
4. தின்தணி – ஥ா ி, தங்குணி (Feb, Mar) 
5. இபந஬ணில் –  ித்஡ித஧, த஬கா ி (Apr, May) 
6. ப௃துந஬ணில் – ஆணி, ஆடி (June, July) 
ப௃க்குற்நங்களும் தபே஬கானங்களும்: 
஬.஋ண் தபே஬கானங்கள் குற்நங்கள் குற்நத்஡ின் ஢ிதன 








3 ப௃ன்தணிகானம் தித்஡ம் ஡ன்ணிதன 
஬பர்ச் ி 




5 இபந஬ணில்கானம் கதம் ந஬ற்று஢ிதன 
஬பர்ச் ி 
6 ப௃துந஬ணில்கானம் ஬ா஡ம் ஡ன்ணிதன 
஬பர்ச் ி 
சூனிக஠த்஡ில் தபே஬கானங்கள்: 
   சூனிக஠த்஡ில் தித்஡ந஡ாடம் தா஡ிப்ததடந்து ஡ன்ணிதன ஬பர்ச் ி 
அதடந்து தின்ணர் ஬பிகுற்நம் ந஬ற்று஢ிதன ஬பர்ச் ி அதடந்து 
அ஡ன்தின் கத஥ாணது ஡ன்ணிதன஬பர்ச் ி அதடந்து சூனிக஠த்஡ின் 
குநிகு஠ங்கள் ந஡ாற்நி஬ிக்கின்நண. 
   ஋ணந஬ கார்கானம் ப௃஡ல் தின்தணி கானம் ஬த஧ப௅ள்ப கானம் சூனி 
க஠ம் ந஡ான்று஬஡ற்குரி஦ கானங்கபாக்கும் (Sep to March) 
஍஬தக ஢ினங்கள்: 
1. குநிஞ் ி (஥தனப௅ம் ஥தன  ார்ந்஡ இடப௃ம்) –  ிநனத்து஥ம் ஡ங்கும் 
2. ப௃ல்தன (காடும் காடு  ார்ந்஡ இடப௃ம்) – ஬ல்தன ஬ா஡ந஢ாய் 
உண்டாக்கும். 
3. ஥பே஡ம் (஬஦லும் ஬஦ல்  ார்ந்஡ இடப௃ம்) – ப௃த்ந஡ாட ந஢ாய்கதப 
எ஫ிக்கும். 
4. த஢ய்஡ல் (கடலும் கடல்  ார்ந்஡ இடப௃ம்) – ஬ா஡ ந஢ாய் குடல் 
஬ாப௅ உண்டாக்கும். 
5. தாதன (஥஠லும் ஥஠ல்  ார்ந்஡ இடப௃ம்) – 
ப௃த்ந஡ாடந஢ாய்களுக்கு இபேப்திடம். 
஋ண்஬தகத் ந஡ர்வு: 
     “஢ாடி தரி ம் ஢ா஢ிநம் த஥ா஫ி஬ி஫ி 





சூனிக஠த்஡ில் ஋ண்஬தக ந஡ர்஬ின் ஢ிதன: 
1. ஢ா –  ஥ஞ் ள் (அ) தச்த  ஥ஞ் ள் ஢ிநம் 
2. ஢ிநம் – ந஡ால், கண், ஢ாம் ஢கம், த஬ளுத்஡ல் 
3. த஥ா஫ி – கு஧ல் எனி ஡ாழ்஡ல் 
4. ஬ி஫ி –  ினந஬தப கண்  ி஬த்஡ல், த஬ளுப்பு, கண் அரிப்பு 
கா஠ல். 
5. ஥னம் – ஥னக்கட்டு 
6. ப௄த்஡ி஧ம் – த஬ண்த஥ கனந்஡ ஥ஞ் ள் ஢ிநத்துடன் த௃த஧ 
கா஠ல் 
7. ஸ்தரி ம் –  ினந஬தப சு஧ம் இபேந்஡ால் ஥ிகு 
த஬ப்த஥ாகவும்  ினந஬தப ஡ட்த஥ாகவும், ஬ி஦ர்த஬ப௅ம் 
காணும். 
8. ஢ாடி – ஬ா஡ கதம், தித்஡ கதம், ஬ா஡ தித்஡ம். 
஢ீர்க்குநி: 
 “அபேந்து ஥ாநி஧஡ப௃ம் அ஬ிந஧ா஡஥஡ாய் 
அக்கல் அனர்஡ல் அகானவூன் ஡஬ிர்ந்஡஫ற் 
குற்நப஬பேந்஡ி உநங்கி த஬கதந 
ஆடிக்கன த் ஡ா஬ிந஦ காதுததய் 
த஡ாபே ப௃கூர்த்஡க் கதனக்குட்தடு ஢ீரின் 
஢ீர்க்குநி த஢ய்க்குநி ஢ிபே஥ித்஡ல் கடநண” 
஬ிபக்கம்: 
஢ீர்க்குநி தார்க்கும் ப௃஡ல் ஢ாள் இ஧வு ஢ன்கு உ஠வு 
உண்஠ ந஬ண்டும்.தின் ஬டீி஦ற்காதன தடிகதாத்஡ி஧த்஡ில் 
஢ீரிதண திடித்து அ஡ன் ஢ீர்க்குநி ஥ற்றும் ஢ிநக்குநி஦ிதண 
கண்ட஧நி஡ல் ந஬ண்டும். 
        “஬ந்஡ ஢ீர் கரித஦தட ஥஠ம் த௃த஧ ஌ஞ் தனன் 
         தநந்஡ி஦லுப஬த஬ ஦த஧குது ப௃தநந஦” 
-ந஢ாய் ஢ாடல்- ப௃஡ல் தாகம் 
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஢ீரில் ஢ிநம் ஥஠ம் த௃த஧, ஋தட ஋ஞ் ல் இ஬ற்தந கா஠ 
ந஬ண்டும். 
த஢ய்க்குநி: 
    “஢ீர்க்குநிக் குத஧த்஡ ஢ிபே஥ாண ஢ீரிற் 
     ிநக்க த஬ண்தணய்ந஦ார்  ிறுதுபி ஢டு஬ிடுத் 
    த஡ன்னுநத் ஡ிநந்஡த஬பி ந஦ாகா ஡த஥ந்஡஡ி 
    ஢ின்ந஡ி஬தன ததாம் த஢நி஬ி஫ி஦நிவும் 
 ிறு஢ீரில் ஢ல்தனண்த஠ய் ஬ிட்டு தார்ப்தது.” 
஬ிபக்கம்: 
க஠ந஢ா஦ாபின்  ிறு஢ீத஧ ந ா஡தண ஬ட்டினில் ஊற்நி, சூரி஦ 
எபி ஥ிகுந்஡ இடத்஡ில் ஢ீரின் அதன஦ில்னா஡நதாது 
஢ல்தனண்த஠ய்த்துபி ஬ிட்டு தார்ப்தது. 
“அ஧த஬ண ஢ீண்டில் ஬ா஡ம் 
ஆ஫ிநதாற் த஧஬ின் தித்஡ம் 
ப௃த்த஡ாத்து ஢ிற்கின் கதம்” 
அ஧வு(தாம்பு) நதால் த஧஬ிணால் ஬ா஡ ஢ீர் ஆ஫ி (ந஥ா஡ி஧ம்) நதால் 
த஧஬ிணால்தித்஡ ஢ீர் ப௃த்து நதால் த஧஬ிணால் கத ஢ீர் ஆகும். 
஢ாடி 
 சூனிக஠த்஡ில்  ஡க ஢ாடி ஢தட: 
஬ா஡ தித்஡ ஢ாடி: 
 “ததாபேபாண ஬ா஡த்஡ில் தித்஡ஞ் ந ர்ந்து 
 ததாபேத்து கு஠ங்கபா ப௃\;஠஬ாப௅ த்஡ி 
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 த ரி஦ாத஥ புபித்ந஡ப்தம் ததாபே஥ல் ஢ீரிற் 
  ி஬ப்பு ஥னம் திடித்஡லுபேந் ஡ாது஢ட்டம் 
 கபே஬ாண ந஡க஥஡ி லுதபச் ல் ந ாம்தல்” 
                             - ஡க ஢ாடி 
஬ா஡ கத ஢ாடி: 
 “தாங்காண ஬ா஡த்஡ில் ந த்து஥ ஢ாடிப் 
 தரி ித்஡ால் ஡ி஥ிர்ந஥வு ப௃தபச் னாகும் 
 ஡ஙீ்காண இபே஥லுடன்  ந்஡ி ந஡ாடம் 
஬ாங்கா஡ ஈதப஥ந் ஡ா஧ கா ம் 
 ஬னிப௅டநண புந஬சீ்சு உள்஬சீ்சு ஬கீ்கம் 
 ஏங்காணுஞ் சு஧ப௃டநண சு஬ா கா ம் 
 உண்டாக்கும் த஬குந஢ாய்க்கு ப௃று஡ி ஡ாநண” 
- ஡க ஢ாடி 
஥பேத்து஬ம்: 
    “ந஢ாய் ஢ாடி ந஢ாய் ப௃஡ல் ஢ாடி அது ஡஠ிக்கும் 
    ஬ாய்஢ாடி ஬ாய்ப்தச் த ஦ல்” 
“ந஢ாய்஢ாடல், ந஢ாய்ப௃஡ணாடல்” இவ்஬ி஧ண்டும் தி஠ித஦ அநி஬஡ற்க்கு 
இன்நி஦த஥஦ா஡து தற்நிப௅ம், அ஡ன் திநகு஡ான் ஥பேந்த஡க் குநிப்திடல் 
ந஬ண்டும். 
    “உற்நாண பவும் தி஠ி஦பவுங் கானப௃ம் 




1. ஡ன்ணிதன ஬பர்ச் ி஦தடந்஡ ஍஦த்த஡ப௅ம், thjj;ijAk; 
 ஥ப்தடுத்஡ ந஬ண்டும். 
2. ஡ன்ணிதன ஬பர்ச் ி஦தடந்஡ தித்஡த்த஡  ஥ப்தடுத்஡ ந஬ண்டும். 
3. ஬ன்த஥ இ஫ந்஡ உடற்கட்டுகதப ஬ன்த஥ அதட஦ச் த ய்ப௅ம் 
஥பேந்஡பிக்க ந஬ண்டும். 
தத்஡ி஦ம்: 
     “தத்஡ி஦த்஡ிணாநன தனனுண்டாம் ஥பேந்து 
      தத்஡ி஦ங்கள் நதாணால் தனன் நதாகும்- தத்஡ி஦த்஡ில் 
 தத்஡ி஦ந஥ த஬ற்நி஡பேம் தண்டி஡ர்க்கு ஆ஡னிணால் 
 தத்஡ி஦ந஥ உத்஡ி த஦ன்று தார்” 
 -ந஡த஧஦ர்  
஥பேந்துண்ணும் கானங்கபில் ந஢ா஦ாபி஦ின் ந஢ா஦ின் ஡ன்த஥ ததாபேத்து 




க஠ம் ந஢ா஦ாபிக்கு ஆகும் கநி ஬ி஬஧ம்: 
  “கண்டு தகாள்஬ார் கநி஬தகக்கு ஬ி஬஧ம் நகளு 
  க஡னிப௅ட கா஦ாகும் ப௃பேங்தகப் திஞ்சு 
  கண்டு  ிறுகீத஧ த஢ல்னிக்காய் ஡ாணாகும் 
  ஡க்க து஬த஧ அ஬த஧ப௅ட திஞ்சு஥ாகும் 
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  தண்டு த஢ய் தால் கற்கண்டு தூதுபங்காய் ஆகும் 
  தரி஬ான் ப௃஦லுடும்தின் இதநச் ி஦ாகும் 
  தகாண்டுடன் த஬ள்பாடு த஬ள்தபனிப௅ம் 
  குனத்஡ிலுள்ப ஬ி஧ால் ஥ ிநி஦ாகும்” 
                       -஥஡தனந஢ாய் த஡ாகு஡ி-ii 
஬ிபக்கம்: 
    ஬ாத஫க்காய் ப௃பேங்தகதிஞ்சு, த஢ல்னிக்காய், து஬த஧, அ஬த஧ப் 
திஞ்சு, 
   தூதுபங்காய், த஢ய், தால், கற்கண்டு, ப௃஦ல் இதநச் ி, உடும்பு 
இதநச் ி, 
   த஬ள்தபனி, ஬ி஧ால்஥ீன், ஥ ிநி  
இத஬ க஠ம் ந஢ா஦ாபிக்கு ஆகும் உ஠வு த஡ார்த்஡஥ாகும். 
ஆகா தத்஡ி஦ம்: 
குபிர்ந்஡ ஢ீர், குபிர்தா஠ங்கள், ஍ஸ்கிரீம், இணிப்பு ஬தககள், ஋பி஡ில் 
த ரிக்கா஡ ஥ாப்தண்டங்கள். தாகல், அகத்஡ிகீத஧, குபிர்ச் ி஦ாண 
காய்கநிகள், ந஢ா஦ாபிக்கு எவ்஬ா஡ த஫஬தககள். 
ந஢ாய் ஡டுப்பு ப௃தந ஥ற்றும் ஥பேத்து஬ம் அநிவுத஧: 
ந஢ா஦ாபி ஡ணக்கு எவ்஬ா஡ ததாபேட்கதப கண்டநிந்து அ஡தண ஢ீக்க 
ந஬ண்டும். 
சுகா஡ா஧஥ற்ந உ஠வு஬தககள் ஥ற்றும் ஢ீரிதண ஡஬ிர்க்கவும். 
குபிர்காற்று, தணிகாற்நில் த஬பி஦ில் த ல்஬த஡ ஡஬ிர்க்கவும். 
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உ஠஬ிதண இபஞ்சூட்டில் உண்஠ ந஬ண்டும் 
இ஧஬ில் உ஠த஬  கீ்கி஧ம் உண்டு  ிநிதுந஢஧ம் த ன்ந தின்பு உநங்க 
த ல்ன ந஬ண்டும். 
ந஢ாய் ஋஡ிர்ப்பு  க்஡ித஦ ஡பேம்  த்துள்ப உ஠வுகதப உண்஠ 
ந஬ண்டும். 
புரிந்து தகாள்ளும் ஬஦஡ிலுள்ப கு஫ந்த஡களுக்கு தி஧ா஠ா஦ா஥ம் 


















CELLULAR DEVELOPMENT OF LUNG IN UTERO 
    At about 26 week of gestation, the lung reaches the stage of full 
maturity at which capable of supporting life the rest of the time spent in in utero from 
26 week to term is for the development and subdivision of the respiratory bronchioles, 
the saccules and for the growth of the air ways 
POST- NATAL DEVELOPMENT:        
   At the time of birth there are very few true alveoli, and gaseous 
exchange takes place through saccules or terminal airspaces. The alveoli start 
appearing after birth,first on peripheral saccules,then towards proximal respiratory 
bronchioles and terminal bronchiole.About 127 million alveoli are present at one year 
and about 280 million alveoli have developed by the age of 8 years. 
PECULARITIES OF RESPIRATORY TRACT IN CHILDREN:  
 Chest wall is thin,elastic, yielding and the intrinsic muscles are weak.Short 
thorax with the ribs running more horizontally. Increase in antero posterior diameter 
of the chest with limited respiration. Epiglottis is longer and projects backwards at a 
greater degree than in older children. 
 All these peculiarities tend to increase the risk of permanent deformity in the 
chest wall in the presence of recurrent or longstanding respiratory distress.By above 8 
years the chest assumes conical shape since the antero posterior diameter is less than 
the transverse diameter and the ribs are placed in a slightly downward direction. 
 ANATOMY & PHYSIOLOGY OF RESPIRATORY SYSTEM 
The respiratory system is a complex biological system comprised of several 
organs that facilitate the inhalation and exhalation of oxygen and carbon dioxide in 
living organisms. 
For all air breathing vertebrates, respiration is handled by the lungs, but these 
are far from the only components of the respiratory system. In fact, the system is 









6. Bronchi and bronchioles 
7. Lungs  
8. The muscles of respiration. 
A properly functioning respiratory system is a vital part of our good health. 
Respiratory infections can be acute and sometimes life threatening. They can also be 
chronic, in which case they place tremendous long term stress on the immune system, 
endocrine system, HPA axis, and much more. 
Anatomical components 
Nose and Nasal cavity 
 The nose and nasal cavity constitute the main external opening of the 
respiratory system. They represent the entryway to the respiratory tract- a passage 
through the body which air uses for travel in order to reach the lungs.  
The nose is made out of bone, muscle, cartilage and skin, while the nasal 
cavity is more or less, hollow space. Although the nose is typically credited as being 
the main external breathing apparatus, its role is actually to provide support and 
protection to nasal cavity. 
 The cavity is lined with mucus membranes and little hairs that can filter the air 
before it goes into the respiratory tract. They can trap all harmful particles such as a 
dust, mold and pollen and prevent them from reaching any of the internal 
components. 
Oral cavity  
The oral cavity, more commonly referred to as the mouth, is the only other 
external component that is part of the respiratory system. Normally, breathing through 
nose is preferable to breathing through the mouth.  
34 
 
Not only does the mouth not possess the ability to warm and moisturize the air 
coming in but it also lacks the hairs and mucus membranes to filter out unwanted 
contaminants. On the plus side, the pathway leading from the mouth is shorter and the 
diameter is wider, which means that more air can enter the body at the same speed. 
Pharynx 
 The pharynx resembles a funnel made out of muscles that acts as an 
intermediary between the nasal cavity and the larynx and esophagus. It is divided into 
three separate sections: (i) Nasopharynx(ii) Oropharynx (iii) Laryngopharynx. 
The nasopharynx is the upper region of the structure, which begins at the 
posterior of the nasal cavity and simply allows air to travel through it and reach the 
lower sections. 
 
The oropharynx does something similar, except it is located at the posterior of 
the oral cavity. Once the air reaches the laryngopharynx, something called the 




The larynx is the next component, but represents only a small section of the 
respiratory tract that connects the laryngopharynx to the trachea. It is commonly 
referred to as the voice box, and it is located near the anterior section of the neck, just 
below the hyoid bone. The aforementioned epiglottis is part of the larynx, as are the 
thyroid cartilage, the cricoid cartilage and the vocal folds. The thyroid cartilage also 
goes by a more common name- the Adam‟s apple- although, contrary to popular 




The trachea is a longer section of the respiratory tract, shaped like a tube and 
approximately 5 inches in length. The trachea, more commonly referred to as the 
windpipe, connects the larynx to the bronchi and also has the role of filtering the air 





The lower end of the trachea splits the respiratory tract into two branches that 
are named the primary bronchi. These first run into each of the lungs before further 
branching off into smaller bronchi. These secondary bronchi continue carrying the air 
to the lobes of the lobes of the lungs, and then further split into tertiary bronchi.  
 
The tertiary bronchi then split into even smaller sections that are spread out 
throughout the lungs called bronchioles. Each one of these bronchioles continues to 
split into even smaller parts called terminal bronchioles. The tiny bronchioles do not 
have any kind of cartilage and instead rely on muscles and elastin. The walls of the 
bronchi and bronchioles are also lined with muscle tissue, which can control the flow 
of air going into the lungs. 
Lungs 
 The lungs are two organs located inside the thorax on the left and right sides. 
They are surrounded by a membrane that provides them with enough space to expand 
when they fill up with air. The left lung is smaller and has only two lobes while the 




Inside the lungs resemble a sponge made of millions of small sacs that are named 
alveoli. These alveoli are found at the ends of terminal bronchioles and are 
surrounded by capillaries through which blood passes.  
Pleura and Pleural Cavity 
The inside of the thoracic cavities and the lung surface are covered with serous 
membranes, respectively the parietalpleura and the visceral pleura, which are in direct 
continuity at the hilum.  
Depending on the subjacent structures, the parietal pleura can be subdivided 
into three portions: the mediastinal, costal and diaphragmatic pleurae. The shape of 
the lungs is determined by the shape of the pleural cavities. Because of the presence 
of pleural recesses, which form a kind of reserve space, the pleural cavity is larger 
than the lung volume. 
The lungs are maintained in close opposition to the thoracic wall by a negative 
pressure between visceral and parietal pleurae. A thin film of extracellular fluid 
between the pleurae enables the lungs to move smoothly along the walls of the cavity 
during breathing. 
Muscles of respiration 
 The last component of the respiratory system is a muscle structure known as 
the muscles of respiration. These muscles surround the lungs and allow the inhalation 
and exhalation of air. The main muscle in this system is known as the diaphragm, a 
thin sheet of muscle that constitutes the bottom of the thorax.  
It pulls in air into the lungs by contracting several inches with each breath. In 
addition to the diaphragm, multiple intercostals muscles are located between the ribs 
and they also help compress and expand the lungs. 
Blood supply 
On the right side there is one bronchial artery which arises either from the 
third posterior intercostals artery or from the third posterior intercostal artery or from 
the upper left bronchial artery. On the left side there are two bronchial arteries both of 
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which arise from the descending thoracic aorta, the upper opposite fifth thoracic 
vertebra and the lower just below the left bronchus. 
The venous blood from the first or two divisions of the bronchi is carried by 
bronchial veins. Usually there are two bronchial veins on each side. The right 
bronchial veins drain into the azygos vein. The left bronchial veins drain either into 
the left superior intercostals vein or into the hemiazygos vein. The greater part of the 
venous blood from the lungs is drained by the pulmonary veins. 
Lymphatic drainage 
Superficial vessels drain the peripheral lung tissue lying beneath the 
pulmonary pleura. The vessels pass round the borders of the lung and margins of the 
fissures to reach the hilum. Deep lymphatics drain the bronchial tree, the pulmonary 
vessels and the connective tissue septa. They run towards the hilum where they drain 
into the bronchopulmonary nodes. 
Nerve supply 
Parasymphathetic nerves are derived from the vagus. These fibers are (i) motor to 
the bronchial muscles and on stimulation cause bronchospasm. (ii) secretomotor to 
the mucous glands of the bronchial tree and (iii) sensory. The sensory fibers are 
responsible for the cough reflex. 
 Sympathetic nerves are derived from second to fifth spinal segments. These 
are inhibitory to the smooth muscle and glands of the bronchial tree. That is how 
sympathetic drugs, like adrenalin, cause bronchodilatation and relieve symptom of 
bronchial asthma. 
RESPIRATION 
During normal quiet breathing, inspiration is the active process and expiration 
is the passive process. During inspiration, thoracic cage enlarges and lungs expand. 





Muscles of Respiration  
The expansion of the chest during inspiration occurs partly voluntary and 
partly involuntary.  The muscles of normal quiet breathing are the intercostal muscles 
and the diaphragm. During difficult breathing they are assisted by the muscles of the 
neck, shoulder and abdomen.  
Cycles of Respiration  





The capacity of the thoracic cavity is increased by simultaneous contraction of 
the inter costal muscles and the diaphragm. The parietal pleura move with the walls of 
thorax and the diaphragm. This reduces the pressure in the pleural cavity to the level 
considerably lower than the atmospheric pressure. The visual pleura follow the 
parietal pleura. During the process, the lungs are stretched; the pressure within the 
alveoli and the air passage reduced drawing air into the lungs in an attempt to equalize 
the atmospheric and alveolar air pressure. 
The process of inspiration is active as it requires expenditure of energy for 
muscle contraction. The negative pressure created in the thoracic cavity aids venous 
return to the heart and is known as respiratory pump.  
Expiration 
Relaxation of inter costal muscles and the diaphragm results in the downward 
and inward movement of the rib cage and the elastic recoil of the lungs. As this 
occurs, the pressure of the gases inside the thorax exceeds the atmospheric pressure 
and therefore air is expelled from the respiratory tract. The lungs still contain some air 
and are prevented from complete collapse by the intact pleura. The process is passive 
as it does not require the expenditure of energy. 
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After expiration there is a pause, before the next cycle begins.  
Physiology Variables Affects Respiration  
Elasticity 
Loss of elasticity of the connective tissue in the lungs necessitates forced 
expiration and increased effort of inspiration.  
Compliance 
The ability of lungs and thorax to expand or the expansibility of lungs and 
thorax is called the compliance. It is defined as the change in volume per unit change 
in the pressure. 
Air flow resistance 
When this is increased e.g. in broncho constriction, more respiratory effort is 
required to inflate the lungs. 
 Pulmonary function tests: 
Pulmonary function tests are useful in assessing the functional status of the 
respiratorysystem both in physiological and pathological conditions. Pulmonary 
function tests are carried out mostly by using spirometer. 
The air in lung is classified into two divisions: 
I. Lung volume 
II. Lung capacities 
Lung volume  
 Lung volumes are the volumes of air breathed by an individual during altered 
pattern of respiration. The lung volumes are dynamic and are four types: 
I. Tidal volume 
II. Inspiratory reserve volume 
III. Expiratory reserve volume 
IV. Residual volume 
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Tidal Volume (TV) 
 The volume of air breathed in and out of lungs in a single normal quiet 
respiration is called tidal volume. Tidal volume signifies the normal depth of 
breathing. Normal value 500 ml 
Inspiratory Reserve Volume (IRV) 
An additional amount of air that can be inspired forcefully after the end of 
normal inspiration beyond tidal volume is called the inspiratory reserve volume. 
Normal volume 3300 ml 
Expiratory Reserve Volume (ERV) 
 The additional amount of air that can be expired out forcefully, after normal 
expiration is called the expiratory reserve volume. Normal volume 1000 ml 
Residual Volume 
Normally, lungs cannot be emptied completely even by forceful 
expiration. Some amount of air always remains in the lungs even after the forced 
expiration. The amount of air remaining in the lungs even after forced expiration 
is called residual volume. 
 It is significant because of two reasons: 
I. It helps to aerate the blood in between breathing and during 
expiration 
II. It maintains the contour of the lungs 
Lung capacities 
 Two or more lung volumes together are called lung capacities. Lung 
capacities are of four types: 
I. Inspiratory capacity 
II. Vital capacity 
III. Functional residual capacity 
IV. Total lung capacity 
41 
 
Inspiratory capacity (IC) 
 It is the maximum volume of air that is inspired from end expiratory 
position. Inspiratory capacity includes tidal volume and inspiratory reserve 
volume.  
IC = TV + IRV=500+3300=3800ml 
Vital capacity (VC) 
 It is the maximum amount of air that is expelled out forcefully after a 
maximal (deep) inspiration. Vital capacity includes inspiratory reserve volume, 
tidal volume and expiratory reserve volume. 
VC= IRV+TV+ERV=3300+500+1000=4800ml 
Functional residual capacity (FRV) 
 It is the volume of air remaining in the lungs after normal expiration. 
Functional residual capacity includes expiratory reserve volume and reserve 
volume. 
                 FRV= ERV+RV=1000=+1200=2200ml 
Total lung capacity (TLC) 
 Total lung capacity is the amount of air present in the lungs after a 
maximal inspiration. It includes all the volumes. 
                        TLC=IRV+TV+ERV+RV=3300+500+1000+1200=6000 
Alveolar Ventilation 
This is the volume of air that moves into and out of the alveoli per minute. It is 
the tidal volume minus the anatomical dead space, multiplied by the respiratory rate. 
Alveolar ventilation = (TV-anatomical dead space) respiratory rate 
= (500-150) ml x 15 per minute = 5.25liters / minute. 
Lungs function tests are carried out to determine respiratory function and are 




This is the exchange between alveoli and blood. Total area of gas exchange in 
the lungs is 70-80 square meters. CO2 diffuses from venous blood along the 
contraction gradient into the alveoli until equilibrium with alveolar air is reached. By 
the same process O2 diffuses from alveoli to the blood.  
Internal Respiration 
This is the exchange of air between the tissue and blood. When there is 
difference in partial pressures, oxygen diffuses outward from the blood to extra 
cellular fluid then into the cell walls. The process involved is diffusion. 
Control of Respiration 
Control of respiration is normally involuntary. Voluntary control is exerted 
during activities such as speaking, singing but is over ridded if homeostasis of arterial 
PO2 and PCO2 is threatened i.e. if this is high arterial PCO2 or low arterial PO2. 
BRONCHIAL ASTHMA  
DEFINITION 
 Bronchial asthma is a common chronic inflammatory condition of the airways 
characterized by increased responsiveness of tracheobronchial tree to a variety of 
stimuli resulting in widespread narrowing of the air space.The term “asthma” in 
Greek means „breathless‟ or „breathe with open mouth‟ 
 PREVALANCE 
 Around 0.5-2 percentage  of the population suffers from asthma 
 8.9 million childrens had been diagnosed  with asthma in their life time , boys 
(14./.) and girls  (10./.) 
 The international study on asthma and allergies in childhood (ISAAC) 
reported prevalence of breathing difficulty in 9./. Of children in rural area of  
Tamilnadu. 




 1. Allergens such as Food, Pollens, Dust, Mites and Pet dander. 
2. Air pollutions and toxins. 
3. Emotional stress and anxiety. 
4. Weather, especially extreme changes in temperature. 
5. Infections bacterial, viral  fungal. 
PATHOPHYSIOLOGY OF ASTHMA 
 The inhalation of an allergen in a sensitized atopic asthmatic patient results in 
a two phase bronchoconstrictor response. The inhaled allergen rapidly interacts with 
mucosal mast cells via IgE dependent mechanism, resulting in the release of 
mediators such as histamine and the cysteinylleukotrienes with resulting 
brochoconstriction. 
 Airway hyper-reactivity is integral to the diagnosis of asthma and appears to 
be related, but not exclusively so to airway inflammation. Other factors are likely to 
be important including the behavior of airway narrowing and the influence of 
neurogenic mechanisms. 
           With increasing severity and chronicity of the disease, remodeling of the 
airway occurs leading to fibrosis of the airway wall, fixed narrowing of the airway 
and a reduced response to bronchodilator medication.Asthma has the following 
pathological characteristics: 
 Airway obstruction (or airway narrowing), that is reversible (at least partially), 
either spontaneously or with treatment. 
 Airway inflammation  
 Airway hyper responsiveness to a variety of stimuli 
Airway obstruction 
 Airway obstruction is responsible for the clinical manifestations of asthma 
such as wheezing, dyspnoea, and cough.  
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 Airway obstruction, which is determined by the diameter of the airway lumen, 
can be influenced by a number of factors, including oedema of the bronchial wall, 
mucus production, airway smooth muscle contraction, and airway remodeling 
suggesting a rationale for early initiation of anti- inflammatory therapy. 
Airway inflammation 
The airways of asthma patients are infiltrated by a number of different 
inflammatory cells, which then cause epithelial disruption and mucosal oedema. An 
initial trigger in asthma may cause the release of inflammatory mediators from 
bronchial mast cells, macrophages and epithelial cells. 
 In addition to the release of cytokines by mast cells, T-cells, fibroblasts, 
endothelial cells and epithelial cells activate neutrophils, eosinophils and 
macrophages, which produce chronic allergic inflammation characteristic of asthma. 
           This process produces epithelial injury, abnormalities in neural mechanisms, 
increase in airway smooth muscle responsiveness, and airflow obstruction. Epithelial 
injury can lead to increased permeability and sensitivity to inhaled allergens, irritants, 
and inflammatory mediators.  
 In addition, transduction of fluids and reduced clearance of inflammatory 
substances and respiratory secretions occur with disruption of epithelium mucociliary 
mechanisms. The inflammatory process may chronically irritate the airway leading to 
chronic cough symptoms. 
Airway hyperresponsiveness:  
Airway hyperresponsiveness is an exaggerated bronchoconstrictor response to 
many physical, chemical and pharmacological agents e.g., allergens, environmental 
irritants, viral respiratory infections: cold air or exercise.  
Whether airway hyperresponsiveness, an abnormality fundamental to the 
pathogenesis of asthma is present at birth in genetically predisposed individuals, or 
whether it is acquired, is under investigation. 
  The level of airway hyperresponsiveness usually correlates with the clinical 
severity of asthma and with medication requirement. Atopy, the genetic predisposition 
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for the development of an IgE mediated response to common aero allergens, is the 
strongest identifiable predisposing factor for developing asthma. 
  The stimuli that interact with airway responsiveness and incite acute episodes of 
asthma can be grouped into ten major categories – allergic, pharmacological, 
environmental, occupational, infections, and exercise – related and emotional stress, 
food and drink, smoking, heart burn. 
Allergens 
An allergy with asthma is a common problem. Eighty percent of people with 
asthma have allergies to airborne substances such as tree, grass, and weed pollens, 
mold, animal dander, dust mites, and cockroach particles. 
Allergic asthma is dependent on IgE response controlled by T and B lymphocytes 
and activated by the interaction of antigen with mast cells-bound IgE molecule. 
Air pollutants 
Children with asthma who are exposed to maternal smoking have higher 
requirements for medication and more frequent emergency department visits. Other 
irritants such as wood smoke, household sprays, volatile organic compounds (e.g. 
polishes and cooking oils), and air pollutants may also exacerbate asthma. 
Respiratory infections 
It is well established that viral respiratory infections can excertable asthma, 
particularly in children with asthma under the age of 10. Respiratory syncytial virus, 
rhinovirus, and influenza virus have been implicated, with rhinovirus being implicated 
in the majority of the exacerbation of asthma in children.  
The role of infections as triggers also appears to be important but not common 
in adults. Respiratory virus may exacerbate asthma through different mechanism. One 
is that viral infections may cause epithelial damage and airway inflammation, both of 
which events may create asthma symptoms.  
In addition, virus has been shown to potentiate the allergic response to 
allergens by increasing the release of inflammatory mediators and the cascade of 




Adverse weather conditions such as freezing temperatures, high humidity, 
thunderstorms and episodes of acute pollution brought out by weather conditions have 
been associated with asthma exacerbations. 
CLASSIFICATION OF BRONCHIAL ASTHMA: 
 Bronchial asthma can be divided in to two types 
 1. Extrinsic asthma (atopic) 
  2. Intrinsic asthma (Non-atopic) 
  3. Mixed type 
1. Extrinsic asthma (Atopic): 
            1.This is the not common type of asthma. 
            2. It is usually begins in childhood or in early adult life.  
            3. It is often associated with a personal and/ or family history of allergic 
diseases such as rhinitis, urticarial and eczema. 
            4. Positive wheal and flare skin reactions to intradermal injections of antigens 
extract and increased level of IgE in serum. 
2. Intrinsic asthma (Non - atopic): 
      1. This type of asthma develops later in adult life with negative personal or 
family history of allergy, negative skin test. 
      2. They have normal serum level IgE 
      3. Nasal polyp and chronic bronchitis are commonly present 






CLINICAL MANIFESTATION:  
CARDINAL SIGN: 
                   The presence of usually diffuse, polyphonic, bilateral and particularly 
expiratory wheeze is the cardinal signs of asthma. 
COMMON SYMPTOMS: 
        1. Expiratory wheeze 
        2. Shortness of breath 
        3. Chest tightness 
        4. Intermittent dry cough 
        5. Dyspnea 
        6. Intermittent non – focal chest pain 
        7. Nocturnal cough 
        8. Decreased physical activity 
        9. General fatigue 
ASSOCIATED SYMPTOMS: 
 Allergic rhinitis 
 Sneezing 
 Itching 
 Nasal congestion 
 Gastro oesophageal reflux 
SEVERE PERSISTENT ASTHMA: 
 Anxiety due to stage of panic 
 Difficulty in talking 
 Increased breathlessness 
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 Silent chest (absence of wheeze)  
 Profuse sweating 
 Pulses paradoxes 
 Cardiac arrhythmias 
 
DIAGNOSIS: 
 The diagnosis of asthma is a clinical one. Hence detailed history,  physical 
examination and additional information‟s regarding family history of atopic, allergic 
exposure, circadian variation and seasonal exacerbation should be carefully 
considered. 
DIFFERENTIAL DIAGNOSIS: 
     Bronchiolitis 
               Aspiration of foreign body 















PREPARATION AND PROPERTIES OF TRAIL DRUGS 
 INTERNAL   MEDICINE 
ATHIMATHURA CHOORANAM: 
INGREDIENTS: 
ATHIMADHURA CHOORANAM is a Herbal Siddha formulation comprising of 
purified  
1 .ATHIMATHURAM (Glycirrhizaglabra)        - 10gm 
2. ELAM   (Elettariacardamomum)                      - 10gm 
3. ELAVANGAPATTAI (Syzygiumaromaticum) - 10gm 
4. SENBAGA MOKKU (Micheliachampaca)       - 10gm 
5. KOTTAM (Costusspeciosus)                             - 10gm 
6. CHUKKU (Zingiberofficinale)                              - 10gm 
7. NAR CHIRAGAM (Cuminumcyminum)           - 10gm 
8. KORAI KIZHANGU (Cyperusrotundus)           - 10gm 
9. SUGAR        -  80gm 
SOURCE OF THE DRUGS: 
                 The required raw drug is procured from a well reputed indigenous drug 
shop and it will be authenticated by the pharmacologist, SCRI Chennai. 
PURIFICATION OF RAW DRUGS: 
                  Raw drugs are purified a mentioned in Sikicharathna Deepam Sarakku 






                  The purified above first 8 raw drugs are made into fine powder as 
mentioned in the literature and finally sugar added.  
DRUG STORAGE:  
                  The trial drug is stored in clean dry air tight container and it is dispensed to 
the patients in packets.  
DOSE: 
 500mg (Twice a day) 
ADJUVANT: 
                   Honey 
DURATION: 
                   21 days 
REFERENCE: 
Balavagadam, Page no: 479, Paadal .No – 41 
PROPERTIES OF TRAIL DRUG: 
1. ATHIMATHURAM: 
Botanical name:Glycyrrhizaglabra 
                     English name: Jamaica liquorice 
Family name:Fabaceae 







 “புத்஡ிக்கு ஬ித்஡ாகுஞ்  ந்஡ாதந் ஡ரீ்க்கும் 
புதகந்த஡டுக் குஞ்ந ட்டு ஥த்த஡ப் தித்஡ ந஧ாகத்த஡ 
அத்஡ிப் தற்நிண ந஥கந்஡ன்தண ஬ா஡த்஡ிதண 
஦றுத்஡ிடும் ஬ச் ி஧த஥ன்தா஧஡ி ஥து஧ந்஡தணந஦” 
ACTIONS: 
                     Demulcent, Emollient, Mild Expectorant, Tonic 
  CHEMICAL CONSTITUENTS: 
Beta glycyrrhetinic acid, Liquiritigenine, Liquiritine, Disodium 
glycyrohetinic acid, glycyricin  etc. 
PHARMACOLOGICAL ACTIVITIES: 
Immuno modulator, Anti-viral, Antitussive, Antioxidant, Antimicrobial, 
Hepatoproductive 
REFERENCE: 
Phytotheraphy Res. 22, 709-724 (2008) Published online in wileyinterscience 
                    DOI: 10.1002/PTR.2362. 
2. ELAM:  
Botanical name :  Electariacardamomum 
English name  :  Cardamom seeds 
Family name  : Zingiberaceae 
Part used  : Seeds 
Suvai   : Kaarpu 
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Thanmai  : Veppam 
Pirivu   : Kaarpu 
ததாதுகு஠ம்: 
த஡ாண்தட ஬ாய் கவுள்஡ாலு கு஡ங்கபில் 
தண்தட த஬க்தக ஬ி஡ாக ந஢ாய்கா ப௃ம் 
அண்தட஦ீதப ஬ன்தித்஡ம் இத஬க்தகல்னாம் 
ஆன஥ாங்க ஥ழ்஌ன ஥பேந்ந஡ 
ACTIONS: 
                    Stimulant, Stomachic 
CHEMICAL CONTITUENTS: 
                    Alpha- pinene,Sabinene,Myrecene, Limonene, Cineole, Cymene, Methyl 
heptenone 
PHARMACOLOGICAL ACTIVITIES: 
         Anti – athmatic, Bronchodilator, Antimicrobial, Antieptic 
 REFERENCE: 
                     A journal of Bangladesh pharmacological society 2011; 6 ;34-37. 
3. ELAVANGAPATTAI: 
Botanical name :  Cinnamomumverum, Presl 
English name  :  Bark of cinnamon 
Suvai   : Kaaram, inipu 
Thanmai  : Thatpam 




 ஡ாதுட்டம் நத஡ி  பே஬஬ி஭ம் ஆகி஦ந஢ாய் 
 பூ஡கி஧கஞ்  ினந்஡ிப்பூச் ி ஬ிடஞ்-  ா஡ி஬ிடம் 
 ஆட்டு஥ித஧ப் நதாடிபே஥ல் ஆகி஦ ந஢ாய்க் கூட்ட஥ந 
 ஏட்டு ஥ின஬ங்கத் துரி 
       ACTIONS: 
                     Stimulant 
       CHEMICAL CONTITUENTS: 
B-pinene, Limonene, Farnesol, Benzaldehyde,  2-heptanone 
       PHARMACOLOGICAL ACTIVITIES: 
           Antioxidant, Antiviral, Antimicrobial 
     REFERENCE: 
  Asian pacific journal of tropical biomedicine, DOI:10.1016/S2221-
1691(14)60215-X 
4. SENBAGA MOKKU: 
Botanical name :  Micheliachampaca.Linn 
English name  :  Yellow chamba 
Part used  :  Bud flower 
Suvai   : Kaippu 
Thanmai  : Veppam 





஬ா஡தித்஡ம் அத்஡ிசு஧ம் ஥ாந஥கம் சுத்஡சு஧ந் 
஡ாது ஢ட்டங் கண்஠஫ற்  ி஡ங்காந஬- ஥ாந஡நகள் 
஡ிண்புறு ஥ணக்கபிப்தாந் ஡ிவ்஦஥ணம் உட்டிணஞ்ந ர் 
 ண்தகப் பூ஬஡ற்குத் ஡ான் 
 ACTIONS: 
Stimulant, Tonic, Demulcent 
CHEMICAL CONSTITUENTS: 




 International journal of enhanced research and science, technology & 
engineering, ISSN: 2319-7463, Vol. 5, Issue 8, Aug- 2016. 
5. KOTTAM: 
Botanical name :  Costus specious 
English name  : Costus root 
Family name  : Zingiberaceae 
Part used  :  Root 
Suvai   : Kaippu, Viruvirupu 
Thanmai  :  Veppam 




ப௃ட்டித஦ழு ப௃தப஬ி஧஠ம் சு஬ா கா ம் 
ப௄டிகத்ந஡ா ட஧வு஥஧ ஬ிடங்கள் ந஥கக் 
கட்டிஅஜ கல்னி ஬ிடதாகம் பூ஡ 
க஠ம்தானகி஧கத஥ாடு ஡ாது஢ட்டஞ் 
ACTIONS: 
                     Stomachic, Expectorant, Tonic, Stimulant 
CHEMICAL CONSTITUENTS: 
                    B–sitosterol, D–glucopyranoside, Diosgenin, Ligogenin, Octacosanicacid 
        PHARMACOLOGICAL ACTIVITIES: 
         Anti – inflammatory 
REFERENCE: 
             Indian journal of medical research, department of pharmacognacy, 
Moradabad – 244 001 
6. CHUKKU: 
 Botanical name :  Zingiberofficinale, Rosc. 
              English name :  Dried ginger 
  Part used  :  Rhizome 
 Suvai   : Kaarpu 
 Thanmai  : Veppam 





சூதன஥ந்஡ம் த஢ஞ்த ரிப்பு ந஡ாட ந஥ப்தம் ஥஫தன 
ப௄னம் இத஧ப்தி பே஥ல் ப௄க்கு஢ீர்- ஬ானகத 
ந஡ாட஥஡ி  ா஧ந்த஡ாடர்஬ா஡ குன்஥஢ீர்த் 
ந஡ாடம் ஆ஥ம் நதாக்குஞ்சுக்கு 
ACTIONS: 
                    Stimulant, Stomachic, Carminative 
  CHEMICAL CONSTITUENTS: 
Paradols, Gingerdiacetates, Gingerdiones, Gingerglycolipids A,B and C, 
Sesquiterpenes 
PHARMACOLOGICAL ACTIVITIES: 
          Bronchodilator, Anti- inflammatory, Antioxidant, Analgesic 
REFERENCE: 
 International journal of pharma and bio science, A.K.Ghosh, volume 2, issue 
1, Mar 2011, ISSN 0975-6299. 
7. NAR CHIRAGAM: 
 Botanical name :  Cuminumcyminum.Linn 
 English name  : Cumin seeds 
 Part used  :  Seeds 
 Suvai   : Inipu 
 Thanmai  : Thatpam 




஬ாந்஡ி ஦பே ிகுன்஥ம் ஬ாய்ந஢ாய் தீனிக஥ித஧ப் 
நதற்நிபே஥ல் கல்னதடப்தினா ஞ ணப௃ட்- ந ர்ந்஡கம்஥ல் 
ஆ ணகுடாரித஦னும்அந்஡க்கி஧க஠ிப௅ம் 
நதா ணகுடாரிப௅ண்஠ப்நதாம்  
 ACTIONS: 
Carminative, Stimulant, Stomachic, Astringent 
CHEMICAL CONSTITUENTS: 
Cuminaldehyde, O-cymene, Limonene, Beta-pinenz, Coumarin 
PHARMACOLOGICAL ACTIVITIES: 
       Antioxidant, Bronchodilator, Immunomodulator 
REFERENCE: 
      IOSR journal of pharmacy, profDr Ali Esmail Al- Snafi, department of 
pharmacology, volume 6, ISSN 2250-3013. 
8. KORAI KIZHANGU: 
 Botanical name :  Cyperusrotundus, Linn. 
            English name  :  Nut grass 
 Family name  : Cyperaceae 
        Part used  :  Root tuber 
 Suvai   : Thuvarpu 
 Thanmai  : Thatpam 




 ஡ீசு஧ந்஡ரீ்க்குஞ் த ம்புணல் தித்஡ம்நதாகும் 
஬ா஡சு஧ந் ஡஠ிக்கும் த஬஦கத்஡ில் 
நகானவு஠த஬க் கு஥஧ணடனினடு 
நகானவு஠த஬க் தகாடு க஦த்த஡ 
ACTIONS: 
        Simulant, Tonic, Demulcent, Astringent 
CHEMICAL CONSTITUENTS: 
       Alpha cyperone, beta – selinene, patchoulenone, cyperene, sugeonol, 
sesquiterpene, routudone 
PHARMACOLOGICAL ACTIVITIES: 
Antipyretic,antidiarrhoeal, antimicrobial, hepatoprotective, antiallergic, analgesic, 
anti- inflammatory, antioxidant 
REFERENCE: 
     International journal of scientific and research publication, volume-3, Issue 
5, may 2013 
                Arch pharm res.2011 Feb; 34 (2); 223-8, Doi;10,1007/s 12272-001-020-z-








MATERIALS AND METHODS 
Approval of the Screening committee and Institutional ethical committee 
(IEC) were   obtained for undertaking the present study. 
 
The study design and the underlying hypothesis and the rights to withdraw 
from the study at any time were informed orally and in writing to all the participants. 
A Single arm open clinical trial was undertaken in OPD of PG department of 
Kuzhanthaimaruthuvam , Govt. Siddha medical college attached with Arignar Anna 
Hospital of Indian Medicine and homoeopathy, Arumbakkam, chennai-106 for a 





            After finishing the toxicity studies 40 cases were selected from the OPD of 
Kuzhanthaimaruthuvam Department, Arignar Anna Hospital of Indian Medicine and 
homoeopathy, Arumbakkam, chennai-106. They were treated with the trail drug 
Athimadhurachooranam and observed for prognosis clinically. 
 
STUDY DESIGN & CONDUCT OF THE STUDY: 
 
Study Type:      An Open Clinical Trail 
StudyPlace:Arignar Anna Hospital of Indian Medicine and homoeopathy 
 Govt.SiddhaMedicalCollege,  
 Arumbakkam, Chennai – 600 106.  
Study Period: 12 months after completion of preclinical studies.  
Sample size:   40 patients. 




POPULATION AND SAMPLE: 
1. Population consist of paediatric patients attending the OPD of Arignar 
Anna Hospital, GSMC, Chennai-106 
2. The sample consist of patients 2 – 7 year age group fulfilling all the 
inclusion criteria and exclusion criteria. 
STUDY PARTICIPANTS: 
INCLUSION CRITERIA: 
 Age 2 to7 years 
 Cough without expectoration 
 Dyspnoea 
 Chest tightness 
 Wheezing 
 Decreased physical activity 
 Poor diet intake 
 
EXCLUSION CRITERIA: 
 Childhood TB 
 Hypersensitivity Pneumonitis 
 Lung abscess  




 Intolerance to the drug and development of adverse reactions during the trial. 
 Patients turned unwilling to continue in the course of clinical trial. 
 Any other acute illness 
 
ASSESMENT AND INVESTIGATION: 
CLINICAL ASSESMENT: 




 Running nose 
 Chest tightness 
 Wheezing 
 Decreased physical activity 









Moothiram – Neerkuri, Neikuri 
LAB INVETIGATION: 
            1. Blood: TC, DC, ESR, HB. 
      2. Urine analysis : Albumin, Sugar, Deposits. 
 
SPECIFIC INVESTIGATION: 
1.Absolute Eosinophil count. 
 2.Peak expiratory flow rate(above 5 years). 
3.Chest X-ray PA view. 
 




 Patients reporting at the OPD associated with clinical features of cough with 
expectoration, dyspnoea, wheezing, chest tightness, running nose, decreased physical 
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activity, poor diet intake are chosen for enrollment based on the inclusion criteria. The 
patient who are enrolled are informed about the study trail drug, possible outcomes of 
the study in the language and terms understandable to them and the informed 
consent/Assent would be obtained from the patient/patients parent using 
consent/assent form. 
 
CONDUCT OF THE STUDY:   
 The trail drug will be given in the OPD department of kuzhanthaimaruthuvam, 
GSMC, Chennai. The patients will be asked to have a regular follow up in the OPD 
once in a7 days. In each and every visit the clinical assessment will be recorded in the 
prescribed proforma. The laboratory investigation will be done before and after 
treatment and recorded in the prescribed format. 
 
DATA COLLECTION FORMS: 
 Required information will be collected from each patient by using following 
forms. 
     Form I    :  Screening and selection proforma 
                  Form II   :  History taking proforma 
      Form III  : Clinical assessment proforma 
      Form IV  : Clinical assessment during and after trial 
      Form V    : Laboratory Investigation proforma 
      Form VI   : Informed consent/Assent form 
      Form VII  : Withdrawal form 
      Form VIII : Patient information sheet 
DATA ANALYSIS: 
              After enrolling the patients in the study a separate file for each patient will be 
maintained and all forms will be kept in the file. Whenever the patient visits OPD 
during the study period necessary entries will be made in the assessment forms. The 
63 
 
data entries and adverse events if any will be monitored by the Head of the 
Department. 
OUTCOME OF TREATMENT 
Primary Outcome: 
              Primary outcome is mainly assessed by comparing the reduction of 
symptoms before and after treatment. 
Secondary Outcome: 
Secondary outcome is assessed by comparing the safety parameters before and after 
treatment. 
ADVERSE EFFECT AND SERIOUS EFFECT MANAGEMENT: 
             If the trial patient develops any adverse reactions the patient will be referred 
to the Pharmacovigilance department of SCRI and documented. For any adverse 
effect the investigator will give the proper management in the OPD. 
ETHICAL ISSUES 
1. Informed consent/Assent will be obtained from the patient/ patient‟s parent or 
guardian after explaining about the clinical trial in an understandable 
language. 
2. After the consent/Assent of the patient or patient‟s parent (through 
consent/Assent form) if they fit in the criteria they will be enrolled in the 
study. 
3. Treatment will be provided free of cost. 
4. The patients who are excluded (as per the exclusion criteria) will be referring 
to OPD. 
 
ANALYSIS OF TRAIL MEDICINE: 
1. The acute and subacute toxicity study was carried out in 
Sathyabamauniversity, Rajiv Gandhi salai, Chennai. 
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2. The pharmacological analysis of trail drug for Antihistmaine, Bronchodilator, 
Immunomodulator activity was carried out in Sathyabama university, Rajiv 
Gandhi salai, Chennai. 
3. The physiochemical analysis was performed in Sathyabamauniversity, Rajiv 
Gandhi salai, Chennai 
4. Observations made from patients with signs and symptoms of the disease and 





















RESULTS AND OBSERVATIONS 
 40 patients with confirmed diagnosis of soolikanam with satisfying the 
inclusion criteria wear enrolled after obtaining written informed consent and were to 
receive “ATHIMATHURA CHOORANAM” with dosage of 500mg twice daily for 
21 days. 
Results were observed with respect to the following criteria: 
1. Age 
2. Sex 
3. Parent‟s socio – economic status 
4. Paruvakaalam 
5. Diet history 
6. Family history 
7. Distribution of lands 
8. Mukkutram 
9. 7 uadlkattugal 
10. Envagaithervugal 
11. Neikuri 
12. Aetiological factors 
13. Clinical features 
14. Results 











1. AGE DISTRIBUTION :  
 
           S.NO 
 
           AGE 
NO.OF CASES 
(OUT OF 40) 
 
PERCENTAGE 
                1.              2 to 3 
years 
             10                 25% 
                2.              4 to 5 
years 
             16                 40% 
                3.              6 to 7 
years 





 Therefore the above table indicates that children under the age group of 4 to 
5years (40%) are mostly affected, 35% children are affected in the age group of 6 to 

























2. SEX DISTRIBUTION :  
 
            S.NO 
 
           SEX 
NO.OF CASES 
(OUT OF 40) 
 
PERCENTAGE 
              1.    Male children             20             50% 




 Among 40 cases of the study 20 were male children (50%) and 20 were female 




























1.  Low income group             18                45% 
2.  Middle income group             15               37.5% 




 According to this study 18 cases (45%) belongs to the low income group, 15 
cases (37.5%) belongs to the middle income group and 7 cases (17.5%) belongs to 
































4. DISTRIBUTION OF PARUVA KAALANGAL :  
 
 
                    
S.NO 
PARUVA KAALANGAL NO.OF CASES 
(OUT OF 40) 
 
PERCENTAGE 
1.  KaarKaalam 
     (Mid Aug to Mid Oct) 
 
           0 
 
              0 
2.  KoothirKaalam 
     (Mid Oct to Mid Dec  ) 
 
           6 
 
             15% 
3.  MunpaniKaalam 
     (Mid Dec to Mid Feb) 
 
          22 
 
             55% 
4.  PinpaniKaalam 
     (Mid Feb to Mid Apr) 
 
          12 
 
             30% 
5.  ElavenilKaalam 
      (Mid Apr to Mid Jun) 
 
           0 
 
              0 
6.  MudhuvenilKaalam 
      (Mid Jun to Mid Aug) 
 
           0 
 




 The table showed the more prevalence of the disease under Munpanikaalam 




















5. DIET HISTORY : 
 
 




(OUT OF 40) 
 
PERCENTAGE 
1.  Vegetarian             8               20% 




 According to diet, high incidence of cases (80%) was noted in mixed diet and 





















(OUT OF 40) 
 
PERCENTAGE 
1.  Positive family history 
 
           25             62.5% 
2.  Negative family 
history 




 Out of 40 cases 25 (62.5%) cases have positive family history and 15 (37.5%) 

























7. DISTRIBUTION OF LANDS : 
 
        S.NO 
 
            THINAI 
NO.OF CASES 
(OUT OF 40) 
 
PERCENTAGE 
1.  Kurinji (Hill)            0              0% 
2.  Mullai (Forest)            0              0% 
3.  Marutham (Fertile)            5             12.5% 
4.  Neithal (Coatal)           35             87.5% 





 According to siddha concept, no diseases occur to the people living in 
Marutham. Incidence of disease in Maruthanilam and Neithalnilam were due to 
altered life style and environment. In addition, the study was conducted in and around 






















8. MUKKUTRA THEORY :  
 




   TYPES OF 
VATHAM 
NO.OF CASES 
(OUT OF 40) 
 
PERCENTAGE 
1.  Pranan              40            100% 
2.  Abanan               2             5% 
3.  Viyanan              18            45% 
4.  Uthanan              40            100% 
5.  Samanan              40            100% 
6.  Naagan              15             37.5% 
7.  Koorman               0              0% 
8.  Kirukiran              40             100% 
9.  Devathathan             20               50% 




 In vatham, all cases had derangement in Pranan, Uthanan, Samanan 
and Kirukiran (100%). Devathathan was deranged in 50%, Viyanan was 
































   TYPES OF PITHAM 
NO.OF 
CASES 
(OUT OF 40) 
 
PERCENTAGE 
1.  Anilapitham            25             62.5% 
2.  Ranjagapitham            22             55%           
3.  Saathagapitham            22             55% 
4.  Pirasagapitham             5             12.5% 





 In pitham, Anilam was deranged in 62.5% of cases, 55% of cases had 
























   TYPES OF KABAM 
NO.OF CASES 
(OUT OF 40) 
 
PERCENTAGE 
1.  Avalambakam             40           100% 
2.  Kilethagam             25           62.5% 
3.  Pothagam             0             0% 
4.  Tharpagam             0             0% 




 In Kabam, Avalambagam was deranged in all patients (100%),Kilethagam 
































  7 UDAL KATTUGAL 
NO.OF 
CASES 
(OUT OF 40) 
 
PERCENTAGE 
1.  Saaram            40              100% 
2.  Senneer            26               65% 
3.  Oon            10               25% 
4.  Kozhuppu             0                0% 
5.  Enbu             0                0% 
6.  Moolai             0                0% 




 In 7 Udalkattugal 100% of the cases had derangement in Saaram, 65% of 




























(OUT OF 40) 
 
PERCENTAGE 
1.  Naa              12              30% 
2.  Niram               4              10% 
3.  Mozhi               0              0% 
4.  Vizhi              10              0% 
5.  Sparisam              12                30% 
6.  Naadi               0              0% 
      A Vaathapitham               6              15% 
      B Vaathakabam               32               80% 
C Pithakabam               2               5% 
7.  Malam               0               0% 




 In Envagaithervugal, Naa and Sparisam were affected in 30% of cases, Vizhi 
affected in 25% of cases, Niram affected in 10% of cases, Vathakabam affected in 




































(OUT OF 40) 
 
PERCENTAGE 
1.  Vaathaneer Spread like snake          5             12.5% 
2.  Pithaneer Spread like ring          5             12.5% 





 Vaathaneer, Pithaneer was observed in 12.5% of cases and Kabaneer was 
















12. AETIOLOGICAL FACTORS OF SOOLI KANAM : 
 






(OUT OF 40) 
 
PERCENTAGE 
1.  Climate changes             5               12.5% 
2.  Respiratory infections             5               12.5 % 
3.  Family history of allergic 
diseases 
            20 50% 
4.  Aggravating factors like 
inhaled allergens, cool 
beverage & ice creams 






 From the above table it is evident that climate changes are the main 
cause of Soolikanam (12.5%). 12.5% of cases have a respiratory infections, 
25% of cases have Aggravating factors like inhaled allergens, cool beverage & 






















13. CLINICAL FEATURES – SIGNS & SYMPTOMS :  
 
The signs and symptoms of patients with soolikanam under the clinical study 





















1. Wheezing 40 100% 3 7.5% 
2. Cough 32 80% 2 5% 
3. Running nose 27 67.5% 2 5% 
4. Decreased 
physical activity 
23 57.5% 1 2.5% 
5. Poor diet intake 25 62.5% 5 12.5% 
6. Chest tightness 20 50% 1 2.5% 
ASSOCIATED SYMPTOMS 
7. Sneezing 10 25% 0 0% 
8. Fever 5 12.5% 0 0% 
9. Pallor 22 55% 2 5% 
10. Shortness 
of breath 

























7.5% 5% 5% 2.5%
12.5%







 Major clinical symptoms reported to be Wheezing (100%) after treatment it 
was reduced to 7.5%. 80% of cases had cough before treatment, after treatment it was 
reduced to 5%. 67.5% of cases had running nose, it was reduced to 5%.57.5% of cases 
had decreased physical activity, it was reduced to 2.5%. 62.5% of cases had poor diet 
intake, it was reduced to 12.5%. 50% 0f cases had chest tightness, it was reduced to 
2.5% & and most of other clinical signs were relieved after treatment.  
14. RESULTS: 
 
      S.NO 
 
         RESULT 
 
NO.OF CASES 
(OUT OF 40) 
 
   PERCENTAGE 
         1.          Good            30          75% 
         2.      Moderate            6          15% 




 75% of cases showed good results and 15% of cases showed moderate 

































1. 6300 Umamaheshwari 4/FC 06.10.16 Good 
2. 6897 Abisha 3/FC 17.10.16 Good 
3. 4561 Siluvaienjal 3/FC 08.11.16 Good 
4. 6695 Rohan 4/MC 16.11.16 Good 
5. 7370 Kamalesh 7/MC 19.11.16 Good 
6. 9591 Athvaithiram 4/MC 26.11.16 Good 
7. 1019 Gowtham 5/MC 02.12.16 Good 
8. 1032 Thansika 4/FC 02.12.16 Moderate  
9. 1068 Kaviya 7/FC 02.12.16 Good 
10. 1106 Abdhulla 5/MC 02.12.16 Good 
11. 1010 Bharathpubendhira 2/MC 02.12.16 Moderate 
12. 5693 Lakshitha 4/FC 24.12.16 Poor  
13. 6637 Kaviya 7/FC 27.12.16 Good 
14. 6450 Shesan 7/MC 27.12.16 Good 
15. 6885 Mahendra 3/MC 28.12.16 Good 
16. 6728 Madhusri 7/FC 28.12.16 Good 
17. 6842 Vignesh 7/MC 28.12.16 Moderate 
18. 7244 Imanuvel 7/MC 29.12.16 Good 
19. 9568 Keerthana 7/FC 07.01.17 Good 
20. 9598 Eesha 4/FC 07.01.17 Good 
21 811 Harikesh 3/MC 13.01.17  Poor 
22 1397 Deepak 4/MC 17.01.17 Good 
23 1418 Sivasakthi 4/FC 17.01.17 Moderate 
24 2037 Aaathesh 4/MC 19.01.17 Good 
25 2258 Harini 3/FC 20.01.17 Moderate 
26 2931 Leelathar 6/FC 23.01.17 Good 
27 2822 Ebrinjoshal 2/FC 23.01.17 Good 
28 2637 Santhoshkumar 6/MC 23.01.17 Good 
29 5939 Jeyasuji 4/FC 04.02.17 Good 
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30 6061 Lavanya 4/FC 04.02.17 Good 
31 6768 Mervinansesh 7/MC 07.02.17 Good 
32 6850 Bharani 7/MC 07.02.17 Good 
33 7810 Pirithvik 2 1/2/MC 08.02.17 Good 
34 7297 Harini 4/FC 09.02.17 Good 
35 6313 Eethil 5/FC 15.02.17 Poor  
36 9874 Nithish 7/MC 18.02.17 Moderate 
37 9798 Rajasree 6/FC 18.02.17 Good 
38 5120 Abdhulla 4 1/2 /MC 08.03.17 Good 
39 6256 Vadivelan 3/MC 13.03.17 Good 

















RY INVESTIGATION REPORT OF THE PATIENTS 
(BLOOD INVETIGATIONS) 
S.NO OP.NO AGE/SEX TC 
(BT)  
DC (BT) TC 
(AT) 
DC (AT) ESR (BT) ESR (AT) HB 
    P% L% E%  P% L% E% ½ 
hr 
1 hr ½ 
hr 
1 hr BT AT 
1. 6300 4/FC 11600 33 57 10 10700 59 47 4 20 42 8 22 9.2 10 
2. 6897 3/FC 6400 44 50 6 6500 55 40 5 10 20 10 15 11.6 11.8 
3. 4561 3/FC 9600 50 41 9 9000 53 42 5 15 22 11 12 12.6 12.8 
4. 6695 4/MC 9800 55 36 9 9600 49 35 6 15 17 10 15 12.4 12.4 
5. 7370 7/MC 6600 46 46 8 6600 47 46 7 3 12 3 12 12.3 13 
6. 9591 4/MC 6600 49 43 8 9900 50 47 3 7 18 7 16 11.3 11.3 
7. 1019 5/MC 6800 41 52 7 6800 49 47 4 4 12 4 12 12.3 12.3 
8. 1032 4/FC 8700 79 17 4 7900 49 47 4 10 18 10 14 12.4 12 
9. 1068 7/FC 7700 58 36 6 7200 49 45 6 3 5 3 5 13 13 
10. 1106 5/MC 9000 40 54 6 9000 60 35 5 20 25 12 15 10.2 10.2 
11. 1010 2/MC 8400 66 29 5 8400 48 49 3 3 10 3 10 15.2 14.6 
12. 5693 4/FC 10100 60 35 5 9100 49 36 5 6 15 6 15 12 12.4 
13. 6637 7/FC 13400 60 33 7 9800 49 48 3 3 6 3 6 10.9 10.9 
14. 6450 7/MC 8600 49 44 7 8600 54 42 4 6 18 6 16 12.7 12.7 
15. 6885 3/MC 11500 36 57 7 10200 56 31 6 5 12 5 12 10.8 10.8 
16. 6728 7/FC 13700 85 11 4 10700 45 41 4 20 45 10 25 13.1 13.1 
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17. 6842 7/MC 13700 76 20 4 10700 46 40 4 10 22 9 20 10.8 10.8 
18. 7244 7/MC 8700 51 41 8 9000 48 47 5 5 18 6 17 11.3 11.7 
19. 9568 7/FC 18000 86 9 5 16000 53 42 5 7 15 6 14 14.7 14.5 
20. 9598 4/FC 9700 58 37 5 9900 58 37 5 14 22 10 23 13.6 13.6 
21 811 3/MC 8900 42 52 6 9000 64 30 6 5 17 5 17 10.6 10.6 
22 1397 4/MC 8000 62 31 7 8500 49 47 4 12 26 10 20 12.6 12.6 
23 1418 4/FC 7300 55 40 5 7900 50 45 5 7 18 7 18 10.8 10.8 
24 2037 4/MC 5400 59 34 7 6900 50 45 5 10 25 11 22 10.7 11.2 
25 2258 3/FC 11000 62 31 7 10900 57 40 3 2 6 2 6 12.7 12.8 
26 2931 6/FC 8300 38 56 6 8300 58 38 4 5 20 5 20 12.3 12.3 
27 2822 2/FC 14100 68 27 5 11100 48 47 5 17 25 13 23 9 11.1 
28 2697 6/MC 6600 47 45 8 6600 47 47 6 5 12 5 12 13.8 13.8 
29 5939 4/FC 3700 65 29 6 6700 59 35 6 5 12 5 12 12.6 12.6 
30 6061 4/FC 8900 56 37 7 8900 50 47 3 13 20 10 20 13.2 13.2 
31 6768 7/MC 11400 70 23 7 11000 60 35 5 7 21 7 21 11.2 11.2 
32 6850 7/MC 5700 48 44 8 6700 54 40 6 12 24 12 24 14.3 14.6 
33 7180 2 1/2/MC 7400 60 32 8 7400 55 40 5 3 5 3 5 11.5 11.5 
34 7297 4/FC 6700 54 38 8 6900 44 52 4 13 20 12 18 13.1 13 
35 6313 5/FC 5900 38 52 10 6900 58 36 6 14 30 11 20 10.8 11.9 
36 9874 7/MC 12700 65 27 8 10700 47 47 6 7 18 7 18 12 12 
37 9798 6/FC 12900 64 27 9 10900 54 42 4 6 18 6 23 13 13 
38 5120 4 1/2 /MC 10000 63 28 9 10100 60 35 5 20 28 12 25 13.8 13.8 
39 6256 3/MC 9800 55 36 9 9900 50 47 3 5 17 5 19 12.4 12.4 






Sooli kanam is a paediatric disease, the clinical features of which are clearly 
described in various Siddha literatures. This disease most probably correlates with 
childhood bronchial athma  
In this study 40 cases were treated at the post graduate Kuzhathai maruthuvam 
department. Siddha methods of diagnosis were carried out and recorded in the 
selection proforma, and the diagnosis was confirmed with the help of modern 
investigations. The patients were treated with the drug “Athimathura chooranam” are 
clearly observed. The observations are discussed here under, 
1. DISTRIBUTION ACCORDING TO AGE: 
 
 This study indicates that children‟s under the age group of 4 to 5years 
(40%) are mostly affected. 
  35% children are affected in the age group of 6 to 7years. 
 25% children are affected in the age group of 2 to 3years. 
 
2. DISTRIBUTION ACCORDING TO SEX: 
 
 Among 40 cases 50% were male children and 50% were female 
children. 
 
3. DISTRIBUTION ACCORDING TO SOCIO ECONOMIC STATUS: 
 
 Among 40 cases, maximum numbers of patients 45% were in low 
income group, 37.5% were in middle income group and 17.5% were 
in high income group. 
 The highest incidence occurred in low income group. Because of 
poverty, malnutrition and unhygienic this disease is more prevalent 






4. DISTRIBUTION ACCORDING TO PARUVA KAALANGAL : 
 
 Among the 40 cases, highest incidence 55% cases were observed in 
Munpani kaalam, 30% cases were observed in Pinpani kaalam and 
15% of cases were observed in Koothir kaalam. 
 
5. DIET HISTORY: 
 
 According to diet hitory high incidence of cases (80%) was noted in 
mixed diet and in vegetarian (20%) cases were noted. 
 
6. FAMILY HITORY : 
 
 According to family history 62.5% of the cases had positive family 
history and 37.5% of the cases had no relavent family history. 
The highest incidence of cases had positive family history. 
 
7. DISTRIBUTION ACCORDING TO LANDS: 
 
 Among the selected cases 87.5% of them were from Neithal land and 
12.5% of them were from marutham land.  
 This is due to the fact that the study was conducted at Chennai. A 
Neithal land and o majority of the cases were from that land. 
 
8. UYIR THATHUKKAL – VATHAM: 
 
 In vatham, all cases had affected in Pranan, Uthanan, Samanan and 
Kirukiran (100%). Devathathan was affected in 50%, Viyanan was 
affected in 45%, Naagan was affected in 37.5%, Abanan was affected 







9. UYIR THATHUKKAL – PITHAM: 
 
 In pitham, Anilam was affected in 62.5% of cases. 
 55% of cases had affected in Ranjagam, Saathagam. 
  Pirasagam was affected  in 12.5% of cases. 
 
10. UYIR THATHUKKAL – KABAM: 
 
 In Kabam, Avalambagam was affected in all patients (100%). 
  Kilethagam was affected in 62.5% of patients. 
 
11. 7 UDAL KATTUKAL: 
 
 Out of 40 cases 100% of the cases had affected in saaram. 
 65% of cases had affected in senneer. 
 255 of cases had affected in oon. 
 
12. ENVAGAI THERVUGAL: 
 
 According to the study Naa and Sparisam were affected in 30% 
of cases. 
  Vizhi affected in 25% of cases. 
  Niram affected in 10% of cases. 
  Vatha kabam affected in 80% of cases. 
  Vatha pitham affected in 15% of cases. 
  Pitha kabam affected in 5% of cases. 
 
13. NEIKURI : 
 
 Among 40 cases Kaba neer was observed in 75% of cases. 





14. AETIOLOGICAL FACTORS OF SOOLI KANAM : 
 
 Among the 40 cases it is evident that climate changes are the 
main cause of Sooli kanam (12.5%). 
 12.5% of cases have a respiratory infection. 
 25% of cases have Aggravating factors like inhaled allergens, 
cool beverage & ice creams. 
 50% of cases have Family history of allergic diseases. 
 
15. CLINICAL FEATURES: 
 Major clinical symptoms reported to be Wheezing (100%) after 
treatment it was reduced to 7.5%. 80% of cases had cough 
before treatment, after treatment it was reduced to 5%. 67.5% 
of cases had running nose, it was reduced to 5%. 57.5% of 
cases had decreased physical activity, it was reduced to 2.5%. 
62.5% of cases had poor diet intake, it was reduced to 12.5%. 
50% 0f cases had chest tightness, it was reduced to 2.5% & and 
most of other clinical signs were relieved after treatment.  
 
16. LAB INVESTIGATIONS: 
 
 Routine examination of blood and urine were done before and 
after treatment.  
 In most of the cases (80%) elevated ESR and Eosinophil count 
was decreased after treatment (90%). 
17. BIOCHEMICAL ANALYSIS: 
 Bio chemical analysis shows no Acid and Basic radicals. 
 
18. PHARMACOLOGICAL ACTIVITY: 
 
 Pharmacological analysis showed the drug has significant 





19. PHYSICO CHEMICAL ANALYSIS: 
 
 Loss on drying at 1050C (%) – 16.7 ± 2.06 
 Total Ash (%) – 6.12 ± 3.76 
 Acid insoluble Ash – 0.56 ± 0.14 
 Water soluble Ah – 1.14 ± 0.19 
 Alcohol Soluble Extractive – 20.35 ± 1.53 
 Water soluble Extractive – 15.54 ± 1.5 
 PH– 7 
 
20. TOXICITY STUDY OF THE DRUG: 
 
 The acute and sub – acute toxicity study of the trial drug was 
carried out in wistar albino rats reveals that the drug has no 
adverse effects, of it is safe to human being. 
21. RESULT: 
 
 Satisfactory improvement was reported in 21 days of 
commencement of treatment. Out of 40 cases 30 cases (75%) 
showed Good response and also remarkable relief of signs and 
symptoms. 
 Moderate result was observed in 6 cases (15%) with reduction 
of signs and symptoms. 
 In 4 cases the result was poor (10%) a there is no significant 
improvement of symptoms.  
 
22. STATISTICAL REPORT: 
 
 Since the p value is significant in all clinical features.So there is 
significant reducing of clinical features among the patients for 
the treatment of Sooli Kanam(Chilhood Bronchial 





      SUMMARY 
1. The aim of the study is to assess the efficacy of trial drug “ATHIMATHURA 
CHOORANAM” for “SOOLIKANAM (CHILDHOOD BRONCHIAL 
ATHMA)” without any adverse effects. 
2. The etiology, pathogenesis, signs and symptoms of Soolikanam have been 
correlated with that of childhood bronchial asthma with evidence of literature. 
3. Clinical diagnosis and selection of cases based on clinical features described 
in Balavagadam text book and also using questionnaire. 
4. The internal medicine chosen for treatment and management of Soolikanam 
was Athimathurachooranam 500mg, twice a day, after food with honey. 
5. The trial drug selection based on its siddha pharmacological action to pacify 
the deranged vetham, pitham and kabamand also due to its 
Immunomodulatory, Bronchodilatory and Antihiastamatic effect of the 
ingrediants. 
6. 40 cases were diagnosed with Soolikanam clinically observed for clinical 
diagnosis, laboratory diagnosis, peak expiratory flow rate during the treatment 
and the results were dealt in the proforma. 
7. Laboratory diagnosis was done by modern methods of examinations. 
8. The treatment covers administration of trial drug according to the age and also 
includes pranayamam. 
9. The documentation of observation made during the clinical study showed that 
the drug is clinically more effective. 
10.  The biochemical analysis    
11. Sterility test by pour plate method of Athimathurachooranam shows no growth 
/ colonies like E-coli, Salmonella, Staphylococcus Aureus and 
PeudomonasAeruginosa. 
12. In the pharmacological analysis, the trial drug Athimathurachooranam had 
significant Anti-histamine, Bronchodilator and Immunomodulator activity 
which controlling the airway hyper responsiveness help to improve the 
patients quality of life. 
13. The physico chemical analysis of the trial drug shows the Loss on drying at 
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C (%) – 16.7 ± 2.06, Total Ash (%) – 6.12 ± 3.76, Acid insoluble Ash – 
0.56 ± 0.14, Water soluble Ah – 1.14 ± 0.19, Alcohol Soluble Extractive – 
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20.35 ± 1.53, Water soluble Extractive – 15.54 ± 1.5, PH – 7, So it shows the 
safe and effectiveness of the drug. 
With these benefits of ATHIMATHURA CHOORANAM is more effective 
























Bronchial asthma is a heterogeneous pulmonary disorder characterized by 
recurrent episodes of cough, breathlessness and wheezing, which may resolve 
spontaneously or after the use of bronchodilator medication. 
Asthma is the leading chronic disease among children in most industrialized 
countries, increasing prevalence and its impact in reducing the quality of life in 
children.  
In this clinical study Athimathura chooranam were taken as Internal medicine 
respectively. Soolikanam (Bronchial asthma) occurs due to alteration in Kaba kutram. 
In Athimathura chooranam most of the drugs have Kaarpu suvai, Kaarpu suvai are 
decrease the Kaba kuttram. So I choose this drug is more effective to reduce the Kaba 
kuttram in Bronchial asthma.  
The treatment of Soolikanam with Athimathura chooranam has showed Good 
response with no adverse effect and ensure to be safe, effective and simple to 
administration. The drugs have antihistamine, Bronchodilator and anti-microbial  
activity. 
Statistically it is concluded that the treatment was effective and significant. 
Clinical results were found to be good improvement was found in 75% of 
cases, moderate in 15% of cases and Poor in 10% of cases. 











III. Bio Chemical analysis of trial medicine Athimathura chooranam 
for Soolikanam (Childhood bronchial asthma) 
Preparation of sodium carbonate extract 
 2 gm of Athimathura chooranam sample is mixed with 5gm of sodium 
carbonate and taken in a 100 ml beaker and 20 ml of distilled water is added. The 
solution is boiled for 10 minutes,cooled and then filtered. The filtrate is called sodium 
carbonate extract. 
S.No Experiment Observation  Inference 
Test for acid radicals 
1A. Test for sulphate: 
2ml of the above prepared 
extract is taken in a test tube.to 
this add 2ml of 
4 % Ammonium oxalate 
solution. 
Absence of white 
precipitate 
Absent 
B. 2ml of extract is added with 2ml 
of dilute Hydrochloric acid until 
the effervescence ceases 
off.Then 2ml Barium chloride 
solution is added. 
Absence of white 
precipitate 
Absent 
2. Test for chloride : 
2ml of extract is added with 
dilute Nitric acid till the 
effervescence ceases.Then 2ml 
of silver nitrate solution is 
added. 
Absence of white 
precipitate 
Absent 
3. Test for phosphate: 
2 ml of the extract is treated 
with 2 ml of Ammonium 
molybdate solution and 2 ml of 













concentrated nitric acid. 
4. Test for carbonate: 
2 ml of the extract is treated 
with 2 ml of Magnesium 
sulphate solution. 
Absence of white 
precipitate 
Absent 
5. Test for sulphide: 
1 gm of the substance is treated 
with 2 ml of concentrated 
Hydrochloric acid. 





Test for Fluoride and 
oxalate : 
2ml of extract is added with 
dilute Acetic acid and 2 ml of 
Calcium chloride solution and 
heated. 
Absence of white 
precipitate 
Absent 
7. Test for Borate : 
2 pinches of the substance is 
made into paste by using 
Sulphuric acid and alcohol 
(95%) and introduced into the 
blue flame. 





TEST  FOR BASIC  RADICALS 
8. Test for lead: 
2 ml of the extract is added 
with 2 ml of Potassium iodide 
solution. 
 




9. Test for copper: 
One pinch of substance is 
made into paste with 
concentrated Hydrochloric 
acid in a watch glass and 
introduced into the non-
luminous part of the flame. 
Absence of  Bluish 
green colored flame 
Absent 
10. Test for aluminium: 
To the 2 ml of extract Sodium 
hydroxide solution is added in 




11. Test for iron: 
To the 2 ml of extract 2ml of 
Ammonium thiocyanate 
solution and 2ml of 
concentrated Nitric acid is 
added. 
Absence of Blood red 
colour 
Absent 
12. Test for zinc: 
To the 2 ml of extract Sodium 
hydroxide solution is added in 
drops in excess. 





13. Test for calcium: 
To the 2 ml of extract 
Ammonium oxalate solution 
solution is added. 







14. Test for magnesium: 
To the 2 ml of extract Sodium 
hydroxide solution is added in 
drops in excess. 




15. Test for ammonium: 
To the 2 ml of extract few ml 
of Nessler‟s reagent and 
excess of Sodium hydroxide 
solution are added. 





16. Test for sodium: 
2 pinches of the substance is 
made into paste by using 
Hydrochloric acid and 
introduced into the blue flame 





17. Test for mercury: 
2 ml of extract is treated with 
2ml of Sodium hydroxide 
solution. 
Absence of Yellow 
precipitate 
Absent 
18. Test for arsenic: 
2 ml of extract is treated with 
2ml of Silver nitrate solution. 





19. Test for starch: 
2 ml of extracts treated with 
weak iodine solution. 
Absence of white 
precipitate 
Absent 
20. Test for reducing sugar 
5ml of Benedicts qualitative 
solution is taken in a test tube 
and allowed to boil for 2 
minutes and added 10 drops of 
the extract and again boiled 
for 2minutes.The colour 
changes are noted. 




























21. Test for alkaloids : 
2 ml of the extract is treated 
with 2ml of Potassium iodide 
solution. 








Project ID  : NRS/AS/0021/01/2017  
Institute  : Govt Siddha Medical College, Chennai 
Sample Name  : AthimathuraChooranam 
Sample ID   : AC 
Percentage Loss on Drying 
10gm of test drug was accurately weighed in evaporating dish .The sample 
was dried at 105
o
C for 5 hours and then weighed. 
Percentage loss in drying = Loss of weight of sample/ Wt of the sample X 100 
 
Determination of Total Ash 
3 g of test drug was accurately weighed in silica dish and incinerated at the 
furnace a temperature 400 ºC until it turns white in color which indicates absence of 
carbon. Percentage of total ash will be calculated with reference to the weight of air-
dried drug. 
Total Ash = Weight of Ash/Wt of the Crude drug taken X 100 
 
Determination of Acid Insoluble Ash 
The ash obtained by total ash test will be boiled with 25 ml of dilute 
hydrochloric acid for 6mins. Then the insoluble matter is collected in crucible and 
will be washed with hot water and ignited to constant weight. Percentage of acid 
insoluble ash will be calculated with reference to the weight of air-dried ash. 
Acid insoluble Ash = Weight of Ash/Wt of the Crude drug taken X 100 
 
Determination of Water Soluble Ash 
The ash obtained by total ash test will be boiled with 25 ml of water for 5 
mins. The insoluble matter is collected in crucible and will be washed with hot water, 
and ignite for 15mins at a temperature not exceeding 450ºC. Weight of the insoluble 
matter will be subtracted from the weight of the ash; the difference in weight 
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represents the water soluble ash. Calculate the percentage of water-soluble ash with 
reference to the air-dried drug. 
Water Soluble Ash = Weight of Ash/Wt of the Crude drug taken X 100 
 
Determination of Alcohol Soluble Extractive 
About 5 g of test sample will be macerated with 100 ml of Alcohol in a closed 
flask for twenty-four hours, shaking frequently during six hours and allowing to stand 
for eighteen hours. Filter rapidly, taking precautions against loss of solvent, evaporate 
25 ml of the filtrate to dryness in a tared flat bottomed shallow dish, and dry at 105ºC, 
to constant weight and weigh. Calculate the percentage of alcohol-soluble extractive 
with reference to the air-dried drug. 
Alcohol sol extract = Weight of Extract/ Wt of the Sample taken X 100 
 
Determination of Water Soluble Extractive 
About 5 g of the test sample will be macerated with 100 ml of chloroform 
water in a closed flask for twenty-four hours, shaking frequently during six hours and 
allowing to stand and for eighteen hours. Filter rapidly, taking precautions against loss 
of solvent, evaporate 25 ml of the filtrate to dryness in a tared flat bottomed shallow 
dish, and dry at 105ºC, to constant weight and weigh. Calculate the percentage of 
water-soluble extractive with reference to the air-dried drug. 
Water soluble extract = Weight of Extract/ Wt of the Sample taken X 100 
 
Determination of pH 
About 5 g of test sample will be dissolved in 25ml of distilled water and 













Final Test report 
S.No Parameter Mean (n=3) SD 
1. Loss on Drying at 105 °C (%) 16.7 ± 2.06 
2. Total Ash (%)  6.12  ± 3.76 
3. Acid insoluble Ash (%) 0.56 ± 0.14 
4. Water Soluble Ash (%) 1.14  ± 0.19 
5. Alcohol Soluble Extractive (%) 20.35  ± 1.53 
6. Water soluble Extractive (%) 15.54  ± 1.5 
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 Sample Preparation 
Athimathurachooranam(AC) was extracted with hydro alcoholic solvent 
(Methanol: water) 6:4 and the extract was subjected to the following analysis 
1) Test for alkaloids: 
Mayer's Test: To the extract, 2ml of mayer's reagent was added, a dull white 
precipitate revealed the presence of alkaloids. 
 
2) Test for coumarins:  
       To 1 ml of extract, 1 ml of 10% sodium hydroxide was added. The presence of 
coumarins is           indicated by the formation of yellow color. 
3) Test for saponins:  
       To 1 ml of the extract, 5 ml of water was added and the tube was shaken 
vigorously. Copious lather formation indicates the presence of Saponins. 
4) Test for tannins:  
       To the extract, ferric chloride was added, formation of a dark blue or greenish 
black color showed the presence of tannins. 
5) Test for glycosides- Borntrager’s Test 
Test drug is hydrolysed with concentrated hydrochloric acid for 2 hours on a 
water bath, filtered and the hydrolysate is subjected to the following tests. To 2 
ml of filtered hydrolysate, 3 ml of choloroform is added and shaken, choloroform 
layer is separated and 10% ammomia solution is added to it. Pink colour indicates 
presence of glycosides. 
6) Test for flavonoids: 
To 0.1ml of the test sample about 5 ml of dilute ammonia solution were been 
added followed by addition of few drops of conc. Sulfuric acid. Appearance of yellow 






7) Test for phenols: 
Lead acetate test: The extract was taken; 3 ml of 10% lead acetate solution was 
added.  A bulky white precipitate indicated the presence of phenolic compounds. 
 
8) Test for cardial glycosides: 
Keller-Killani Test: Plant extract treated with 2 ml glacial acetic acid containing a 
drop of         FeCl3 .A brown colour ring indicates the presence of positive test. 
 
9) Test for steroids: 
To the test solution 2ml of chloroform was added with few drops of conc. 
Sulphuric acid (3ml), and shaken well. The upper layer in the test tube was turns into 
red and sulphuric acid layer showed yellow with green fluorescence. It showed the 
presence of steroids. 
10) Test for Quinones:  
The extracts were treated separately with Alc. KOH solution. Appearance of 
colors ranging from red to blue indicates the presence of Quinones. 
 
11) Test forCyanins 
A. Aanthocyanin: 
       To 2 ml of the leaf extract, 1 ml of 2N sodium hydroxide was added and heated 
for 5 min at 100 Cᵒ. Formation of bluish green colour indicates the presence of 
anthocyanin. 
B.Betacyanin: 
To 2 ml of the leaf extract, 1 ml of 2N sodium hydroxide was added and heated 
for 5 min at 100
O
C.  Formation of yellow colour indicates the presence of 
betacyanin. 
12) Test for Carbohydrates - Benedict’s test 
To 0.5 ml of test drug about 0.5 ml of Benedic‟s reagent is added. The mixture 
is heated on a boiling water bath for 2 minutes. A characteristic coloured precipitate 






13) Test for terpenoids: 
Salkowski test: 5ml of extract was mixed in 2ml of chloroform, and concentrated 
sulphuric acid was carefully added to form a layer.  A reddish brown colouration 






































































+   Indicates positive 
- Indicates Negative 
 
Reference 
Brain KR, Turner TD. The Practical Evaluation of Phytopharmaceuticals. 










STERILITY TEST BY POUR PLATE METHOD 
Objective  
 The pour plate techniques were adopted to determine the sterility of the 
product. Contaminated / un sterile sample (formulation) when come in contact with 
the nutrition rich medium it promotes the growth of the organism and after stipulated 
period of incubation the growth of the organism was identified by characteristic 
pattern of colonies. The colonies are referred to as Colony Forming Units (CFUs).   
Methodology 
 About 1ml of the test sample was inoculated in sterile petri dish to which 
about 15 mL of molten agar 45
o
C were added. Agar and sample were mixed 
thoroughly by tilting and swirling the dish. Agar was allowed to completely gel 
without disturbing it. (about 10 minutes). Plates were then inverted and incubated at 
37
o




No growth was observed after incubation period. Reveals the absence of specific 
pathogen 
Result 




Test Specification Result Method 
E-coli Absent Absent As per AYUSH 
specification Salmonella Absent Absent 
























TOXICITY  STUDY 
 
PROJECT REPORT ON TOXICITY PROFILING OF ATHIMATHUR 
CHOORANAM 
 
ACUTE TOXICITY STUDY 
Acute toxicity study of the study drug Athimathura chooranam was carried 
out as per OECD guideline (Organization for Economic Co-operation and 
Development) Guideline-423. 
ANIMAL: 
Healthy adult Wistar albino rat weighing between 170-200 g were used for the 
study.  The animals were housed in poly propylene cages and were kept in well 
ventilated with 100% fresh air by air handling unit (AHU). A 12 light / dark cycle 
were maintained .Room temperature was maintained between 22 + 2
0 
Cand relative 
humidity 50–65%. They were provided with food (Sai feeds, Bangalore, India) and 
water ad libitum. All the animals were acclimatized to the laboratory for 7 days prior 
to the start of the study. 
The experimental protocol was approved by The Institutional Animal Ethics 
Committee of Sathyabama University, Chennai, Tamil Nadu, India. 
ACUTE TOXICITY STUDY: 
Acute toxicity study will be carried out in accordance with OECD guideline 
423 
1
. The animals were fasted overnight with free access to water. The study was 
conducted with single oral dose administration of Athimathura chooranam.  
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ANIMAL GROUPING: 
One group consist of 6 female rats were used for this study. The dose utilized 
for evaluation of acute toxicity study is about 2000 mg/kg higher than that of the 






GROUP I : Animals received Test drug 2000 mg/kg (p.o)  
The animals were fasted overnight (12- 16 hrs) with free access to water. The 
study was conducted with single oral administration of study drugAthimathura 
chooranam 2000mg/kg (p.o). The animals were observed continuously for first 72 h 
and then 14 days for emerging signs of behavioral changes, body weight changes and 
for mortality. 
Occurrence of toxicity in animals were observed continuously for the first 4 to 
24 h and observed periodically for the next 14 days.  Observation includes the change 
in skin, fur, eyes and mucus membrane. Appearance of C.N.S,C.V.S and A.N.S related 
toxicity such as tremors, convulsions, sedation, steric behavior, respiratory distress, 
cardiovascular collapse, response to sensory stimuli, salivation, diarrhea, lethargy, 
sleep, coma and mortality were observed with special attention. 
Body weight was recorded periodically. At the end of the experiment all 
animals were subjected for gross necropsy and observed for pathological changes. 
 
SUB-ACUTE TOXICITY STUDY 





Healthy adult Wistar albino rat weighing between 170-200 g were used for the 
study.  The animals were housed in poly propylene cages and were kept in well 
ventilated with 100% fresh air by air handling unit (AHU). A 12 light / dark cycle 
were maintained .Room temperature was maintained between 22 + 2
o 
Cand relative 
humidity 50–65%. They were provided with food (Sai feeds, Bangalore, India) and 
water ad libitum. All the animals were acclimatized to the laboratory for 7 days prior 
to the start of the study. 
The experimental protocol was approved by The Institutional Animal Ethics 








Animals were divided into three groups of 06 animals each consist of 3 male 
and 3 female rats. 
GROUP I : Animals received saline 5 ml/kg b.w (p.o)             
GROUP II :Animals received low dose of test drug 200 mg/kg (p.o) 
GROUP III :Animals received high dose of test drug 400 mg/kg (p.o) 
The animals were randomly divided into control group and drug treated 
groups for two different doses viz. low dose (200 mg/kg b.w) and high dose (400 
mg/kg b.w). 
The animals were administrated with the study drug once daily for 28 days. 
The animals in group I (control group) received normal saline 5 ml/kg b.w. The 
animals in group II received low dose of Athimathura chooranam 200 mg/kg b.w 
(p.o) and group III received high dose of Athimathura chooranam 400 mg/kg b.w 
(p.o). 
The rats were weighed periodically and observed for signs of toxicity pertains 
to C.N.S, C.V.S, A.N.S including behavioral changes, food - water intake and 
morphological changes. At the end of 28
th
 day, the animals were fasted for overnight 
with free access to water. On 29
th
 day the animals were sacrificed with excess 
anesthesia. Blood samples were collected from aorta and stored in EDTA 
(ethylenediamine –tetra actate) for Hematological analysis and for serum generation 
for biochemical analysis. 
The vital organs including heart, brain, lungs, spleen, kidneys, liver, stomach, 
testes, and ovary were harvested and carefully examined for gross lesions. The organs 
were preserved in 10% formalin for histopathological assessment and interpretation. 
 
HEMATOLOGICAL ANALYSIS: 
Blood samples were analyzed using established procedures and automated 
Bayer Hematology analyzer. Parameters evaluated include Packed Cell Volume 
(PCV), Red Blood Cells (RBC) count, White blood cell count (WBC), Platelet Count, 
Hemoglobin (Hb), Mean cell Haemoglobin Concentration (MCHC), Mean Red Cell 
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Volume (MCV), Mean Cell Hemoglobin (MCH), Mean platelet volume (MPV), 




Serum samples were analyzed for High Density Lipoprotein (HDL), Low 
density Lipoprotein (LDL) , Very low density Lipoprotein (VLDL) , Triglycerides 
(TGL), Total Cholesterol , Blood urea nitrogen (BUN), Creatinine, Albumin, Total 
Protein, Glucose, Uric acid, Aspartate Transaminase (AST), Alanine amino 
Transaminase (ALT) and Alkaline  Phosphatase (ALP) using Mind ray auto analyzer 




 Organs included of heart, brain, lungs, spleen, kidneys, liver, stomach, testes 
and ovary. Histological slides of organs were made and observed under the 
microscope.  The pathological observations of cross section of these organs were 
performed on gross and microscopic bases. Histological examinations were performed 
on the preserved tissues with particular emphasis on those which showed gross 
pathological changes. 
STATISTICAL ANALYSIS: 
The statistical analysis was carried by one way ANOVA (GRAPH PAD 
PRISM 5 computer program). Results were expressed as mean ± standard error .A 
statistical comparison was carried out using the Dunnet‟s test for the control and 
treatment group.  
FECAL PELLET ANALYSIS 
METHODOLOGY 
 
Rats of control and treatment group were allowed to explore to open field on clean 
and sterile Stainless steel tray. The collected pellets were analyzed for consistency, 




















MUSCLE GRIP STRENGTH ANALYSIS 
 The grip strength test is a simple non-invasive method designed to evaluate rat 
muscle force in vivo. Rats of control and drug treated group was allowed to hold the 
pull bar with both the hind limbs firmly then the animal was gently pulled back with 
the tail until the animal lost the grip toward the bar. The procedure was repeated to get 
the average value. Muscle grip ness of the drug treated group was compared to that of 
the control rat to ensure the change in coordination.  
 
 
Sub-Acute Toxicity Study 
Analysis Group I Group II Group III 
Consistency Soft Soft Soft 
Shape Oblong Round Head Round Head 
Colour 
Brownish 
green Brownish green Brownish green 
Mucous Shedding Absence Absence Absence 
Blood Cells Absent Absent Absent 
Signs of Infection 
None 
Observed None Observed None Observed 
Analysis Group I 
Consistency Soft 
Shape Oblong 
Colour Dark Brown 
Mucous Shedding Absence 
Blood Cells Absent 
Signs  of Infection None Observed 
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METABOLIC CAGE FOR URINE COLLECTION 
 Rat of control and treatment group was placed individually in metabolic cage 
with free access to feed and water. Urine dropping from the animal was collected 
using specialized wire mesh system fixed at the base of the cage having provision to 
trap the fecal pellet mixed with urine sample. The collected urine sample was 
subjected to analysis with respect to colour, pH, glucose, ketone bodies, pus and 
blood cells. 
RESULTS 
Assessment of clinical signs in rats treated with Athimathura chooranam on 
Acute toxicity study 
Acute 
Parameter Group I 
Clinical Signs Parameters for the duration of 
14 days Test Drug 2000mg/kg 
Number of animals observed 6 Female  
Lacrimation Absence 
Salivation Absence 
Animal appearance Normal 
Tonic Movement Absence 
Clonic Movement Absence 
Laxative action Absence 
Touch Response Normal 
Response to Sound Normal Response 
Response to Light Normal Response 
Mobility Normal Response 
Respiratory Distress Nil 
Skin Color Normal 
Stereotype behavior Absence 
Piloerection Absence 




Open field behavior Normal 
Giat Balancing Normal 
Freezing Behaviour Absent 
Sings of Stress and Anxiety None Observed 
Muscular coordination Normal 




Social Behavior Normal 
Urine Analysis No Abnormality 
Urine Colour Yellowish 
Urine pH 6 
Urine -Glucose                         Absence 
Urine -Ketones                        Absence 
Urine- Bilirubin                         Absence 
Urine-Blood  Cells       Negative 
Urine - Pus cells Negative 
Mortality Nil 
 
Quantitative data on the body weight of rats treated with Athimathura 





Weight in Gms 












Values are mean ± S.D (n = 6 per group). Statistical significance carried out using one 
way ANOVA followed by Dunnett‟s test. 
 
Assessment of clinical signs in rats treated with Athimathura chooranam on Sub-
Acute toxicity study 
SUB ACUTE 
Parameters Group I Group II Group III 
Clinical Signs Parameters 





Number of animals 
observed 
3 Males and 
3Females  
3 Males and 
3Females  
3 Males and 
3Females  
Lacrimation Absence Absence Absence 
Salivation Absence Absence Absence 
Animal appearance Normal Normal Normal 
Tonic Movement Absence Absence Absence 
Clonic Movement Absence Absence Absence 
Laxative action Absence Absence Absence 
Touch Response Normal Normal Normal 





















Respiratory Distress Nil Nil Nil 
Skin Color Normal Normal Normal 
Stereotype behavior Absence Absence Absence 
Piloerection Absence Absence Absence 
Limb Paralysis Absence Absence Absence 
Posture Normal Normal Normal 
Open field behavior Normal Normal Normal 
Giat Balancing Normal Normal Normal 
Freezing Behaviour Absent Absent Absent 
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Sings of Stress and Anxiety None Observed None Observed None Observed 
Muscular coordination Normal Normal Normal 
Muscle grip Normal Normal Normal 
Sedation Absence Absence Absence 
Social Behavior Normal Normal Normal 
Urine Analysis No Abnormality No Abnormality 
No 
Abnormality 
Urine Colour Yellowish Yellowish Yellowish 
Urine pH 6 7 7 
Urine -
Glucose                         Absence Absence Absence 
Urine -
Ketones                        Absence Absence Absence 
Urine- 
Bilirubin                         Absence Absence Absence 
Urine-Blood  Cells       Negative Negative Negative 
Urine - Pus cells Negative Negative Negative 
Mortality Nil Nil Nil 
 
Effect of Athimathura chooranamon Body weight of Rats in Sub-acute toxicity 
study 
Group I 
Before Treatment Weight in 
Gms 
After Treatment 
Weight in Gms 
Mean 184 195.5 
Std. Deviation 5.177 5.958 
Std. Error 2.113 2.432 
Group II 
Before Treatment Weight in 
Gms 
After Treatment 
Weight in Gms 
Mean 181 188.5 
Std. Deviation 6.812 6.686 





Group III Before Treatment 
After Treatment 
Weight in Gms 
Mean 187 196.2 
Std. Deviation 3.578 4.75 
Std. Error 1.461 1.939 
 
Values are mean ± S.D (n = 6 per group of which 3 males and 3 females). Control and 
treatment groups were compared statistically using one way ANOVA followed by 
Dunnett‟s test. 
Quantitative data on the food and water intake of rats treated with Athimathura 
chooranam for 28 days in Sub-acute toxicity study 
GROUP I Food intake Water intake 
Mean 17.42 22.25 
Std. Deviation 3.573 6.437 
Std. Error 1.787 3.219 
GROUP II Food intake Water intake 
Mean 15.92 27.83 
Std. Deviation 1.258 4.238 
Std. Error 0.6292 2.119 
GROUP III Food intake Water intake 
Mean 17.75 28.67 
Std. Deviation 1.912 3.127 
Std. Error 0.9562 1.563 
 
Values are mean ± S.D (n = 6 per group of which 3 males and 3 females). Control and 























MCV                       
(fl) 
MCH            
(pg) 
MCHC          
(g/dl) 
HGB         
(g/dl) 
Mean 9.933 6.6 679.8 58.83 19.22 32.75 13.27 
Std. 
Deviation 1.483 1.103 174.3 6.218 2.232 1.299 1.089 
















MCV                       
(fl) 
MCH            
(pg) 
MCHC          
(g/dl) 
HGB         
(g/dl) 
Mean 11.32 6.633 967.7 62.73 19.27 32.73 13.8 
Std. 
Deviation 2.912 0.8524 132.8 5.742 2.374 1.129 0.998 
















MCV                       
(fl) 
MCH            
(pg) 
MCHC          
(g/dl) 
HGB         
(g/dl) 
Mean 11.2 5.567 943.8 62.52 20.18 32.4 15.12 
Std. 
Deviation 1.051 0.3983 336 4.371 2.666 2.018 1.023 
Std. Error 0.429 0.1626 137.2 1.784 1.089 0.8238 0.4175 
 
Values are mean ± S.D (n = 6 per group of which 3 males and 3 females). Control and 






Effect of Athimathura chooranam on Haematology profile of rats in sub-acute 
toxicity study. 
GROUP I 
Lymph        
(%) 
Mon            
(%) 








MPV     
(fl) 
Mean 80.92 3.6 2.5 1.667 0.1667 5.833 
Std. Deviation 6.151 0.9033 0.6033 0.2251 0.4082 1.14 
Std. Error 2.511 0.3688 0.2463 0.09189 0.1667 0.4652 
GROUP II 
Lymph        
(%) 
Mon            
(%) 








MPV     
(fl) 
Mean 69.47 3.333 2.433 1.483 0.5 5.433 
Std. Deviation 8.468 0.814 0.709 0.2317 0.5477 1.111 
Std. Error 3.457 0.3323 0.2894 0.09458 0.2236 0.4536 
GROUP III 
Lymph        
(%) 
Mon            
(%) 








MPV     
(fl) 
Mean 84.57 3.517 2.533 1.433 0.3333 6.4 
Std. Deviation 7.382 1.311 0.6861 0.2251 0.5164 0.8 
Std. Error 3.014 0.535 0.2801 0.09189 0.2108 0.3266 
 
Values are mean ± S.D (n = 6 per group of which 3 males and 3 females). Control and 











Effect of Athimathura chooranam on Serum Bio-chemistry profile of rats in sub-






























Mean 77 18.83 0.6833 117 74.33 69.17 31.33 16.45 
Std. 
Deviation 6.066 2.317 0.1722 4.942 5.888 3.545 5.007 2.971 






























Mean 81.83 17.67 0.8 118 93.33 65.17 35.83 17 
Std. 
Deviation 16.09 2.733 0.2 12.24 9.564 6.338 11.02 2.309 






























Mean 79 15.83 0.7167 116.2 76.33 60.5 40.33 15.38 
Std. 
Deviation 13.34 3.92 0.1941 8.908 8.14 7.969 12.06 2.304 
Std. Error 5.447 1.6 0.07923 3.637 3.323 3.253 4.924 0.9407 
 
Values are mean ± S.D (n = 6 per group of which 3 males and 3 females). Control and 









Effect of Athimathura chooranam on Serum Bio-chemistry profile of rats in sub-








(g/dl) (AST)  
(IU/ml) 
(ALT)               
(IU/L) 
(ALP)         
(IU/L) 
Mean 6.35 3.6 102.3 36.5 112 
Std. Deviation 0.9995 0.08944 13.87 7.714 15.47 








(g/dl) (AST)  
(IU/ml) 
(ALT)               
(IU/L) 
(ALP)         
(IU/L) 
Mean 6.4 3.733 98.5 27.33 116.2 
Std. Deviation 0.9839 0.5574 13.28 10.35 19.87 








(g/dl) (AST)  
(IU/ml) 
(ALT)               
(IU/L) 
(ALP)         
(IU/L) 
Mean 5.95 3.7 94.5 22.33 126.5 
Std. Deviation 0.8803 0.498 18.44 4.179 21.57 
Std. Error 0.3594 0.2033 7.527 1.706 8.804 
 
Values are mean ± S.D (n = 6 per group of which 3 males and 3 females). Control and 











Quantitative data on absolute organ weight of rats treated with Athimathura chooranamfor 28 days in Sub-acute toxicity study. 
GROUP I 
HEART                 
(gms) 






BRAIN   
(gms) 
LUNG    
(gms) 








Mean 0.7683 5.948 1.617 0.5667 1.483 1.6 1.15 1.833 0.8667 
Std. 
Deviation 
0.05636 0.9834 0.2137 0.1633 0.1472 0.3162 0.501 0.4933 0.4041 
Std. Error 0.02301 0.4015 0.08724 0.06667 0.06009 0.1291 0.2045 0.2848 0.2333 
GROUP 
II 
HEART                 
(gms) 






BRAIN   
(gms) 
LUNG    
(gms) 








Mean 0.5883 5.27 1.45 0.7167 1.65 1.533 1.067 2.567 0.7667 
Std. 
Deviation 
0.09347 0.9016 0.2881 0.1835 0.1871 0.3011 0.459 0.8622 0.5508 
Std. Error 0.03816 0.3681 0.1176 0.07491 0.07638 0.1229 0.1874 0.4978 0.318 
GROUP 
III 
HEART                 
(gms) 






BRAIN   
(gms) 
LUNG    
(gms) 








Mean 0.615 5.745 1.65 0.7 1.45 1.767 1.033 2.867 0.5 
Std. 
Deviation 
0.1377 0.7471 0.1871 0.2098 0.1871 0.1862 0.3011 0.7234 0.1 
Std. Error 0.0562 0.305 0.07638 0.08563 0.07638 0.07601 0.1229 0.4177 0.05774 
Values are mean ± S.D (n = 6 per group of which 3 males and 3 females) for Heart, Liver, Kidney, Brain, Spleen, Lung, Stomach.   Values are 
mean ± S.D (n = 3 per group per sex ) for testes , ovary and uterus for Control and treatment groups were compared statistically using one way 
ANOVA followed by Dunnett‟s test. 
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HISTOPATHOLOGY OF BRAIN (FEMALE RAT) IN SUB-ACUTE 
TOXICITY STUDY 
High Power Magnification 40X 
 
   
GROUP I  GROUP II     GROUP III 
 
Histopathology of Heart (Female Rat) in Sub-acute toxicity Study 









Histopathology of Kidney (Female Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
 
   
GROUP I  GROUP II    GROUP III 
 
Histopathology of Liver (Female Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
   







Histopathology of Lung (Female Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
   
GROUP I  GROUP II    GROUP III 
 
Histopathology of Brain (Male Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
   








Histopathology of Heart (Male Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
   
GROUP I  GROUP II    GROUP III 
 
 
Histopathology of Kidney (Male Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
   







Histopathology of Liver (Male Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
   
GROUP I  GROUP II    GROUP III 
 
HISTOPATHOLOGY OF LUNG (MALE RAT) IN SUB-ACUTE TOXICITY STUDY 
High Power Magnification 40X 
 
   









 Regular marginal alignment on the neurons with promising histology .Neurons 
is very intact and there were no signs of edema or degeneration. No signs of ischemia 
or lesion were observed in sample belongs to group I,II and III. 
HEART  
 Appearance of cardiomyocyte was normal with dark nuclear region. The 
nuclei of muscle fibers appear regular arrangement. No evidence of necrotic 
myocardium were observed in samples belongs to group I, II and III 
LUNG  
 Perivascular region appears normal, Alveolar septa and wall appeared widen 
and normal. No signs of airway secretion and bronchial secretion. Bronchial blood 
vessels and connective tissue appears normal with no sings of pulmonary edema were 
observed in both control and treated rats. 
STOMACH  
 Microscopic analysis of stomach sample reveals normal anatomy of muscular 
stomach with epithelial layer keratinized stratified squamous epithelium, Lamina 
propria and Sub-mucosa were observed in sample belongs to group I, II and III. 
LIVER  
 Liver parenchyma appears normal with no evidence of necrosis. Cytoplasm 
appears normal with widen portal tract. Hepatocellular architecture was normal with 
no signs of necrosis were observed in in sample belongs to group I, II and III. 
SPLEEN  
 Erythropoietic cells (EP) are scattered throughout the red pulp of both the 






 Arrangement of glomerular loop was normal with regular interstitium. Lumen 
of vessels and bowman‟s space appears normal. Appearance of Podocytes and parietal 
epithelium in the glomeruli appears normal in sample belongs to group I,II and III. 
TESTES  
 Normal sertoli cell aligned properly on the basement membrane with oval 
dome shaped nucleus shows the normal morphology of the seminiferous tubule were 
observed in sample belongs to group I,II and III. 
UTERUS 
 Appearance of endometrium, myometrium and uterine glands was normal. 
Arrangement of stratum basale, functionale and surface epithelium seems normal in 
samples belongs to group I,II and III. 
OVARY 
  Histopathological analysis of ovary showing normal corpus luteum (CL) and 
Primordial follicles with few mature ovarian follicles with no signs of abnormality. 
Appearance of antral follicle, primary oocyte and secondary follicles are normal in 






IV. PHARMACOLOGICAL  ACTIVITY 
Final Docking result Analysis 
     
Cyclooxygenase 1 
Receptor 
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Out of three compound‟s Liquirtin has 9 interactions (90%) similar to that of the standard Ibuprofen hence it has promising  COX 1 inhibition 
activity similarly other compound Glabridin  has  80% percentage and compound asparagine has 60 % similar interaction to that of the standard 





Cyclooxygenase 2 Receptor 
  




Amino Acid Sequence 
  5 Celecoxib 54 GLN 55 TYR 56 LYS 57 CYS 67 GLU 
1 3 Asparagine 53 ASP 54 GLN 55 TYR 67GLU   
3 1 Glabridin 37 CYS 38 SER 40 PRO 56 TYR 68 ASN 
2 2 Liquirtin 55 TYR 67 GLU 68 ASN     
 
Out of three compound‟s Asparagine has 3 interactions (60%) similar to that of the standard Celecoxib hence it has promising  COX 2 inhibition 
activity similarly other compound Liquirtin  has  40% percentage and compound glabridin  has 20 % similar interaction to that of the standard 









Amino Acid Sequence 
  5 Diclofenac 57 LEU 59 TYR 61 GLN 119 TYR 151 TYR   
1 4 Asparagine 59 TYR 60 SER 61 GLN 119 TYR 120 LEU 151 TYR 
1 4 Glabridin 59 TYR 61 GLN 119 TYR 120 LEU 151 TYR   
1 4 Liquirtin 59 TYR 61 GLN 119 TYR 120 LEU 151 TYR   
 
Out of three compound‟s Asparagine, glabridin and liquirtinhas 4 interactions (90%) similar to that of the standard Diclofenac hence all three 














Amino Acid Sequence 
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Out of three compound‟s glabirdinhas 2  interactions (50%) similar to that of the standard Diclofenac hence it has promising  IL6 inhibition 
activity similarly other compound Liquirtin  and asparagine has  25% percentage similar interaction to that of the standard hence all three 










Amino Acid Sequence 
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Out of three compound‟sLiquirtine has 14 interactions (90%) similar to that of the standard Citrazinehence it has excellent  Histamine 1 blocking 
activity. similarly other compounds Asparagine and glabirdinhas 8  interactions (53%) similar to that of the standard Citrazinehence all three 










Amino Acid Sequence 
  5 Salicylic acid  35 PRO 38 TYR 40 PRO 54 ARG 55 TYR     
0 0 Asparagine 468 LYS 474 PRO 499 ASP         
2 3 Glabridin 38 TYR 40 PRO 42 GLN 55 TYR 68 ASN 70 THR 468 LYS 
1 5 Liquirtin 35 PRO 38 TYR 40 PRO 42 GLN 54 ARG 55 TYR 68 ASN 
 
Out of three compound‟s Liquirtinhas 5 interactions (100%) similar to that of the standard salicylic acid  hence it has excellent  Prostaglandin 
Synthaseinhibition activity similarly other compound glabirdin has 60% percentage similar interaction to that of the standard hence both 
compounds has Prostaglandin Synthase inhibition activity. Compound Asparagine has no Prostaglandin Synthase inhibition activity. 
Conclusion 
Based on the results of the computational analysis it was concluded that the compound’s such as Asparagine, Liquiritin , Glabridin  
present in the formulation AthimathuraChooranam possess significant inhibition of COX 1& 2 ,Prostaglandin synthases, Histamine 




ICP-MS- Heavy Metal Analysis Report 
ICP-MS 
Inductively Coupled Plasma Mass Spectrometry (ICP-MS): ICP-MS is a type 
of mass spectrometry that is highly sensitive and capable of the determination of a 
range of metals and several non-metals at concentration below one part in 1012 (parts 
per trillion). Samples are decomposed to neutral elements in high temperature argon 
plasma and analyzed based on their mass to charge ratios. It is an automated, simple 
and unique quantitative and qualitative analysis. It measures elemental isotopes ratio. 
Procedure 
Digestion of sample is carried out by transforming 2.5 ml of the sample into a 
closed beaker and 5 ml of concentrated HNO3 was added and digested to near 
dryness. 16 M nitric acid was further added each time to the sample and digested until 
the clear solution was obtained. 5ml of 12 M Hydrochloric acid was added to ensure 
complete digestion .The digested solution was cooled to room temperature and made 
to the final volume of 100 ml with deionized water. Sample solutions were then 
filtered through membrane (0.45micron) filter. Finally, the digested samples were 
used for metal analysis using inductively coupled plasma Mass Spectrometry (Perkin 
Elmer DRC-e Model) .Each sample was digested in triplicate. A blank solution was 
also prepared in a similar manner. 
 
Machine Model: Agilent 7700 ICPMS 
Sample ID: AC 
Element Concentration (mg/L) Upper Limit (mg/L) 










1. Smille TJ and Khan IA, A Comprehensive approach to Identifying and 
authenticating Botanical Products, Clinical Pharmacology and therapeutics. 
2010; 87(2): 175-186. 
2. Limmatvapirat CJ, Charoenteeraboon, Phaechamud T. Simultaneous analysis 
of eleven heavy metals in extracts of Sonneratiacaseolaris (L.) Engl. By ICP-




















BIO STATISTIC REPORT 
 
TREATMENT FOR SOOLI KANAM(CHILHOOD BRONCHIAL ASTHMA): 
The most popular non parametric statistical tool, namely, McNemar Test 





Clinical Features Before Treatment After Treatment 
n% n% 
1. Wheezing 40(100) 3(7.5)** 
2. Cough 32(80) 2(5)** 
3. Running nose 27(67.5) 2(5)** 
4. Decreased physical 
activity 
23(57.5) 1(2.5)** 
5. Poor diet intake 25(62.5) 5(12.5)* 
6. Chest tightness 20(50) 1(2.5)** 
7. Sneezing 10(25) 0(0)** 
8. Fever 5(12.5) 0(0)* 
9. Pallor 22(55) 2(5)**  
10. Shortness of breath 3(7.5) 1(2.5)* 
McNemat test, C.I: 95%, *P<0.05; **P<0.01 
Software: spss17 version 
Number of cases: 40 
Inference:  
Since the p value is significant in all clinical features.So there is significant 
reducing of clinical features among the patients for the treatment 
ofSooliKanam(Chilhood Bronchial asthma).Hence it is concluded that the 
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GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST- GRADUATE DEPARTMENT OF  KUZHANTHAI MARUTHUVAM 
AN OPEN CLINICAL STUDY ON SOOLI KANAM (CHILDHOOD 
BRONCHIAL ASTHMA) IN CHILDRAN WITH THE 
EVALUATION OF SIDDHA TRAIL DRUG ‘ATHIMADHURA 
CHOORANAM’’ 
 
FORM l - SCREENING AND SELECTION PROFORMA 
1.OP NO:  ................................................................. 
2. NAME:  ………………………………………….  
3. AGE:      ………       4.GENDER: …………....... 
5. F.OCCUPATION: ………………………………..      6.F.INCOME:   
………………… 
7. ADDRESS:    ……………………………………  
…………………………………… 
…………………………………… 
8. CONTACT NO:    …………………………………… 
 INCLUSION CRITERIA: 
 Age 2 to7 years                              Yes/No           
 Cough without expectoration Yes/No 
 Dyspnoea Yes/No 
 Running nose  Yes/No         
 Chest tightness Yes/No                             
 Wheezing                                        Yes/No                            
 Decreased physical activity Yes/No                           
 Poor diet intake Yes/No  
• Patients who are willing to sign the informed consent stating that she will 
conscientiously stick to the treatment during 20days but can opt out of the trial of her 
own conscious discretion.    Yes / No 
EXCLUSION CRITERIA 
(Clinical history) 
 Childhood TB 
 Hypersensitivity Pneumonitis 
 Lung abscess  
 Cystic fibrosis 
 Bronchiolitis 
 
ADMITTED TO TRIAL: 








Date:        
Station: 







GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST- GRADUATE DEPARTMENT OF  KUZHANTHAI MARUTHUVAM 
AN OPEN CLINICAL STUDY ON SOOLI KANAM (CHILDHOOD 
BRONCHIAL ASTHMA) IN CHILDRAN WITH THE 
EVALUATION OF SIDDHA TRAIL DRUG ‘ATHIMADHURA 
CHOORANAM’’ 
FORM lI -HISTORY TAKING PROFORMA 
1. SERIAL NO OF THE CASE: …….   2.OP/IP NO: 
....................................................   
3. NAME: ………………………………………… 4. AGE: …….. 5. GENDER: 
…….. 
5. F. OCCUPATION: ………………………………      6.F. INCOME: 
7. COMPLAINTS& DURATION:   
 
8. PERSONAL HISTORY: 
 
9. HISTORY OF PREVIOUS ILLNESS 
 
 
10. BIRTH HISTORY 
 
11.DIETARY HABIT:    1. Vegetarian 
2. Non-vegetarian 
12. FAMILY HISTORY: 
Whether this problem runs in family? 
  1. Yes                               2.No         
If yes, mention the relationship of affected person(s) --------------------- 
History of previous investigations if any ------------------------------ 
 
Date:          
Station 
 



















GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST- GRADUATE DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
AN OPEN CLINICAL STUDY ON SOOLI KANAM (CHILDHOOD 
BRONCHIAL ASTHMA) IN CHILDRAN WITH THE 
EVALUATION OF SIDDHA TRAIL DRUG ‘ATHIMADHURA 
CHOORANAM’’ 
FORM III ASSESSMENT PROFORMA 
1. SERIAL NO: …………………   
2.OP / IP NO: ......................................   
3. NAME: ……………………………   4.AGE: ……     5.GENDER: .................            
 
GENERAL EXAMINATION: 
Height (cms)                : ………………………….                   
Weight (kg)    : ………………………….                   
Temperature(°F)     : ………………………….                   
Pulse rate(/min)   : ………………………….                   
Heart rate(/min)   : ………………………….                   
Respiratory rate(/min)  : ………………………….                   
Blood pressure(mm/Hg)       : ………………………….           







Jugular vein pulsation 
SYSTEMIC EXAMINATION 
Cardiovascular System  : ………………………….                   
 
Respiratory system   : ………………………….                   
 
Gastro-intestinal system  : ………………………….                   
 
CentralNervous System  : ………………………….                   
 
Urogenital system   : ………………………….                   
 
Endocrine System   : ………………………….                   
 
SIDDHA SYSTEM OF EXAMINATIONS: 




4. Thonthaudal   
2. NILAM:  [LAND WHERE PATIENT LIVED MOST] 
 1. Kurinji (Hilly terrain)                                   
 2. Mullai (Forest range)                       
 3. Marutham  (Plains)                            
4. Neithal (Coastal belt)                    
 5. Paalai (Arid regions) 
3. KAALAM: 
1. Kaarkaalam  4.Pinpani kaalam 
2. Koothirkaalam  5. Ilavenilkaalam 
3. Munpanikaalam  6.Muthuvenil kaalam 
4. GUNAM: 
 1.Sathuvam 2.Raasatham             3.Thaamatham 
5. IMPORIGAL (SENSORY ORGANS): 
                                                                        Normal/Affected 
Mei     - ----------------------------------------------- 
Vaai       ----------------------------------------------- 
Kann  -------------------------------------------------------- 
Mukku ------------------------------------------------------- 
Sevi ------------------------------------------------ 
6. KANMENDHIRIYAM (MOTOR ORGANS): 
Kai    ----------------------------------                
Kal    ------------------------------------ 
Vaai  ------------------------------------ 
Eruvai  ---------------------------------- 
Karuvaai  --------------------------------- 








































10. ENVAGAI THERVU: 
I. NAADI: [PULSE PERCEPTION]         
II. SPARISAM: [PALPATION] 
III. NAA: [TONGUE] 
 IV.NIRAM: [COMPLEXION]   
 1. Vadham 
 2. Pitham 
 3. Kabam 
V.MOZHI: [VOICE] 
1. High Pitched 
2. Low Pitched 
                        3. Medium Pitched 
VI.VIZHI: [EYES] 














Date:      
Station: 













  GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST- GRADUATE DEPARTMENT OF  KUZHANTHAIMARUTHUVAM 
AN OPEN CLINICAL STUDY ON SOOLI KANAM (CHILDHOOD 
BRONCHIAL ASTHMA) IN CHILDRAN WITH THE 
EVALUATION OF SIDDHA TRAIL DRUG ‘ATHIMADHURA 
CHOORANAM’’ 
.FORM IV : LABORATORY INVESTIGATIONS PROFORMA 
1. SERIAL NO OF THE CASE: …………………   
2.OP / IP NO: ......................................   
3. NAME: ……………………………   4.AGE: ……     5.GENDER: .................   
A) BLOOD INVESTIGATIONS: 




Hb ( gm/dL)   
ESR (mm) ½ hr.   
 
1 hr.   
T.WBC (Cells / Cu.mm)   
Differential 
Count (%) 
Polymorphs   
 
Lymphocytes   
 
Monocytes   
 
Eosinophils   
 




B) URINE INVESTIGATIONS: 
URINE 
INVESTIGATIONS 
BEFORE TREATMENT AFTER TREATMENT 
Albumin   
          Sugar   




Date:          
Station: 














GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
AN OPEN CLINICAL STUDY ON SOOLI KANAM 
(CHILDHOOD BRONCHIAL ASTHMA) IN CHILDRAN WITH 
THE EVALUATION OF SIDDHA TRAIL DRUG 
‘ATHIMADHURA CHOORANAM’ 
FORM V: INFORMED CONSENT FORM 
“I have read the foregoing information, or it has been read to me. I have 
had the opportunity to ask questions about it and any questions I have asked have 
been answered to my satisfaction. 
            I   consent voluntarily to participate my chid in this study and understand 
that I have the   right to withdraw from the study at any time without in any way it 
affecting my chid further medical care”. 
"I have received a copy of the information sheet/consent form". 
Date: 
Signature of the participant: 
In case of illiterate participant 
  “I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm 







 Signature of a witness                                    Left thumb Impression of the Participant     
(Selected by the participant bearing no connection with the survey team)       
Date:    
Station:                                                                                  
Signature of participant:                                                 
 

















GOVERNMENT SIDDHA MEDICAL COLLEGE, 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI-106 
POST- GRADUATE DEPARTMENT OF  KUZHANTHAI MARUTHUVAM 
AN OPEN CLINICAL STUDY ON SOOLI KANAM 
(CHILDHOOD BRONCHIAL ASTHMA) IN CHILDRAN WITH 
THE EVALUATION OF SIDDHA TRAIL DRUG 
‘ATHIMADHURA CHOORANAM’ 
  FORM VI - WITHDRAWAL FORM 
SI NO: 
OP / IP NO:                                               
NAME: 
AGE / GENDER : 
DATE OF TRIAL COMMENCEMENT: 
DATE OF WITHDRAWAL FROM TRIAL: 
REASONS FOR WITHDRAWAL: 
 Intolerance to the drug and development of adverse reactions during the trial. 
 Patients turned unwilling to continue in the course of clinical trial. 
 Any other acute illness. 
Date:          
Station: 







GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST- GRADUATE DEPARTMENT OF  KUZHANTHAI MARUTHUVAM 
AN OPEN CLINICAL STUDY ON SOOLI KANAM (CHILDHOOD 
BRONCHIAL ASTHMA) IN CHILDRAN WITH THE 
EVALUATION OF SIDDHA TRAIL DRUG ‘ATHIMADHURA 
CHOORANAM’’ 
FORM VII – PATIENT INFORMATION SHEET 
Name of Co-Investigator;P.Chakravarthi.         Name of the college: 
Govt.SiddhaMedical  College 
 Arumbakkam 
 Chennai-106. 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL. 
 I,P.Chakravarthi, studying M.D (Siddha) at Govt.Siddha Medical College, 
Chennai,  is doing a clinical trial on ‘‘SooliKanam (Childhood Bronchial Asthma) in 
children . It is becoming a most common disease, occurring throughout the world. In 
this regard, I am in need to ask you few questions. I will maintain confidentiality of 
your comments and data obtained. There will be no risk of disclosing your identity 
and no physical, psychological or professional risk is involved by taking part in this 
study. Taking part in this study is voluntary. No compensation will be paid to you for  
taking  part in this study. 
           You can choose not to take part. You can choose not to answer a specific 
question. There is no specific benefit for you if you take part in the study. However, 
taking part in the study may be of benefit to the community, as it may help us to 
understand the problem of defaulters and potential solutions. 
             If you agree to be a participant in this study, you will be included in the study 
primarily by signing the consent form and then you will be given the internalmedicine 
"Athimadhurachooranam" (Internal medicine) 500 mg b.d with Honey for 7 days. 
 The information I am collecting in this study will remain between you and the 
Co- investigator (myself). I will ask you few questions through a questionnaire. I will 
not write your name on this form. I will use a code instead. 
The questionnaire will take approximately 20 minutes of your time. 
If you wish to find out more about this study before taking part, you can ask 
me all the questions you want orcontact P.Chakravarthi, PG Scholar cum Co- 
investigator of this study, attached to Govt. Siddha Medical College, Chennai-106. 
You can also contact the Member-secretary of Ethics committee, Govt.Siddha 

















GOVERNMENT SIDDHA MEDICAL COLLEGE
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST- GRADUATE DEPARTMENT OF  KUZHANTHAI MARUTHUVAM 
AN OPEN CLINICAL STUDY ON SOOLI KANAM (CHILDHOOD 
BRONCHIAL ASTHMA) IN CHILDRAN WITH THE 
EVALUATION OF SIDDHA TRAIL DRUG ‘ATHIMADHURA 
CHOORANAM’’ 
FORM X - ADVERSE REACTION REPORTING FORM 
SERIAL NO:                                                                                                           
OP/IP NO: 
NAME:                                                    AGE:                                          GENDER: 
DATE OF TRIAL COMMENCEMENT: 
DATE OF OCCURRENCE OF THE ADVERSE REACTION:  TIME: 





Date:                                                                              
Station: 




XI.CASE SHEET PROFORMA  
GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST- GRADUATE DEPARTMENT OF  KUZHANTHAI MARUTHUVAM 
AN OPEN CLINICAL STUDY ON SOOLI KANAM (CHILDHOOD 
BRONCHIAL ASTHMA) IN CHILDRAN WITH THE 
EVALUATION OF SIDDHA TRAIL DRUG ‘ATHIMADHURA 
CHOORANAM’’ 
Branch -IV KUZHANTHAI MARUTHUVAM  
PROFORMA OF CASE SHEET FOR KANAM 
IP. No  :    Nationality  : 
Name   :    Religion  : 
Age   :    Date of Admission : 
Sex   :    Date of Discharge : 
Address    :    Diagnosis  : 
Informant  :    Medical Officer : 
1. Complaints and duration   :    
2. History of present illness   :    
3. History of previous illness  :    
4. Antenatal history   :     
5. Birth history    :    
6. Neonatal history   :    
7. Development history   : 
8. Nutritional  history   : 
9. Socio environmental history  : 
10. Family history    : 
11. Immunization history   : 
 
Clinical examination General examination 
1. Consciousness   : 
2. Stature    : 
a. Height   : 
b. Weight  : 
c. Head circumference : 
 d. Mid arm circumference : 
   e. Chest circumference :  
 
3. Nourishment   : 
4. Anaemia    : 
5. Cyanosis    : 
6. Clubbing    : 
7. Jaundice    : 
8. Lymphadenopathy   : 
9. Abdominal distension  : 
10. Pedal oedema   : 
 
Vital Sign 
1. Temperature  : 
2. Pulse rate  : 
3. Respiratory rate : 
4. Heart rate  : 
5. Blood pressure  : 
 Siddha aspect  
 Nilam 
1. Kurinji  : 
2. Muilai  : 
3. Marutham  : 
4. Neithal  : 
5. Palai   : 
Parvakalam 
1. Kaar   : 
2. Koothir   : 
3. Munpani  : 
4. Pinpani   : 
5. Elavenil   : 
6. Muthuvenil  : 
Poripulangal   
1. Mei  : 
2. Vai  : 
3. Kan  : 
4. Mooku  : 
5. Sevi  : 
Kanmenthiriyam  
1. Kai  :  
2. Kaal  : 
3. Vaai  : 
4. Eruvai  : 
5. Karuvai  : 
Uyirthathukkal 
Vadham 
1. Praanan   : 
2. Abaanan   : 
3. Viyaanan   : 
4. Uthaanan   : 
5. Samaanan   : 
6. Nagan   : 
7. Koorman   : 
8. Kirukaran   : 
9. Devathatthan  : 
10.   Dhananjeyan  : 
Pitham 
1. Anal Pitham  : 
2. Ranjagam   : 
3. Saadhagam  : 
4. Praasagam   : 
5. Aalosagam   : 
Kabam 
1. Avalambagam  : 
2. Kilethagam  : 
3. Pothagam  : 
4. Tharpagam  : 
5. Santheegam  : 
Udarkattugal 
1. Saaram   : 
2. Senneer  : 
3. Oonn   : 
4. Kozhuppu  : 
5. Enbu   : 
6. Moolai   : 
7. Sukkilam / Suronitham:  Not applicable 
Ennvagaithervugal 
1. Naadi   : 
2. Naa   : 
3. Niram   : 
4. Mozhi   : 
5. Vizhi   : 
6. Sparisam  : 
7. Malam   : 
8. Moothiram  : 
 
Modern Aspects  
Respiratory System  
      1. Inspection  : 
2. Palpation  : 
3. Percussion  : 
4. Auscultation  : 
Examination of other system 
Cardiovascular system  
Abdomen 
Central nervous system 
Laboratory investigations  
Blood 
TC    : 
DC    : 
ESR   : 
1
/2hr,  : 
1 hr  : 
 
Hb%  : 
Urine 
 Albumin   : 
 Sugar    : 
Deposit  : 
 
Stools 
Ova   :  
Cyst   : 
Other Investigations 
X-ray- chest PA view:  
Mx test  : 
Investigation - Siddha aspect 
Neerkuri and Neikuri : 
1. Neerkuri 
Niram   : 
Edai   : 
Manam  : 
Nurai   : 
Enjal   : 
2. Neikuri Daily progress 
Date Symptoms Medicine 
   
 
 





Glycirrhiza glabra Elettaria cardamomum 
 




Michelia champaca Cuminum cyminum 
 
Zingiber officinale Syzygium aromaticum 
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